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INTRODUCTION 
The purpose of this group of papers is to present 
an up-to-date review of common urologic problems 
that confront the primary care physician. Two papers 
are presented on urinary tract infections, the most 
common complaint faced by physicians in their 
offices. Another paper covers congenital anomalies 
of the urinary tract which represent an important 
part of pediatric diseases. Dr. William McRoberts, 
one of the McGuire Lecturers, reviews aspects of 
male infertility, a significant concern in today's so-
ciety. Other topics discussed in this issue are paren-
chymal kidney disease, the management of the 
patient with end-stage renal disease, and urinary 
tract cancer. These subjects are both timely and 
important in the every day practice of the primary 
care physician. 
The Female Urethral Syndrome and 
Urethritis and Prostatitis in the Male 
STEPHEN N . ROUS, M.D. 
Professor and Chairman, Department of Urology, M edica/ University of South Carolina, Charleston, South 
Carolina 
Two common urological problems frequently 
encountered by the primary care physician are the 
female urethral syndrome and urethritis in the male. 
Although I will touch on chronic prostatitis in this 
discussion , I question whether it is anything but a 
relatively uncommon entity. 
FEMALE URETHRAL SYNDROME 
While the female urethral syndrome is neither 
life-threatening nor even serious, it causes great dis-
comfort to the patient and is probably the most com-
mon genitourinary (GU) complaint bringing women 
to the primary care physician . Combined with cystitis 
it may account for as many as two thirds of the 
outpatient visits to the urologist, at least in my expe-
rience. 
The symptoms of the syndrome are: 
I. Frequency of voiding with or without burn-
ing, 
2. Discomfort in the region of the urethra, 
3. Pressure low in the pelvis, 
4. Urgency and/or nocturia, and 
5. Terminal dysuria. 
By far the most common symptom is the frequency of 
urination with or without burning, and it may occur 
with any or all of the other symptoms. 
Anatomically, the female urethra is homologous 
to the prostatic urethra, proximal to the ejaculatory 
This is an edited transcript of the lecture delivered by Dr. 
Rous at the 49th Annual McGuire Lecture Series, December 3, 
1977, at the Medical College of Virginia, Richmond, Virginia. 
Correspondence and reprint requests to Dr. Stephen N. Rous, 
Department of Urology, Medica l University of South Carolina, 
Charleston, SC 29403. 
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duct. It is about 3 to 5 cm in length and is surrounded 
by suburethral and paraurethral glands, the ducts of 
which empty for the most part into the distal portion 
of the urethra near the urethral meatus. Normally, 
the urethra is colonized by a certain number of in-
troital bacteria, usually limited to the distal portion 
of the urethra, and when the bacteria are limited to 
this area, there are usually no symptoms. However, 
when bacterial colonization extends to the proximal 
suburethral and paraurethral glands, the symptoms 
of the female urethral syndrome occur. 
Diagnosis 
When a patient comes to the physician with 
symptoms of the female urethral syndrome, diagnos-
tic evaluation should be based on the following pro-
cedures: 
I. Urinalysis and urine cultures. The findings in a 
patient with one or more symptoms will usually show 
a modest pyuria of 15 to 20 white cells per high power 
field . Culturing the urine-aerobic, anaerobic and, in 
selected cases, acid fast-is imperative because, un-
less negative cultures, which are a feature of the syn-
drome, are established, the patient's symptoms may 
be confused with bacterial cystitis. 
2. Urograms and cystograms. When symptoms 
persist, an excretory urogram should be done. Usu-
ally the results will be normal, b.ut occasionally there 
will be a patient with a stone in the distal ureter that 
can produce the symptoms of urgency and frequency . 
While the patient's bladder is full of the contrast 
medium that has come down from the kidneys, she 
should also be asked to void under x-ray control. 
This will often demonstrate whether or not a urethral 
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diverticulum exists, and the presence of one can 
sometimes mimic the symptoms of the syndrome. If a 
urethral diverticulum is suspected, the patient should 
additionally undergo a retrograde urethrogram. 
3. Vaginal examination. Not only is a vaginal ex-
amination important to check for gynecological pa-
thology but it is useful specifically to detect the pres-
ence of a urethral diverticulum . This is a readily 
detectable mass which varies in size from a pea to a 
golf ball and is found in the midline on the anterior 
vaginal wall. It may or may not have stones in it. 
4. Cystoscopy and urethroscopy. These proce-
dures establish conclusively the diagnosis of the fe-
male urethral syndrome. In appearance the urethra 
will look very similar to a red cobblestone road and 
this is called a granular urethritis; the pathology 
sometimes extends up into the trigone and is then 
called a granular urethro-trigonitis . 
Treatment 
There are several ways in which to treat the 
female urethral syndrome. Systemic antimicrobial 
therapy is usually unsuccessful because the anti-
microbials are not able to penetrate the suburethral 
and paraurethral glands in sufficient quantities. How-
ever, with some of these patients I have used Fura-
cin* Urethral Inserts® which put the antimicrobial 
agent in direct proximity to the suburethral and para-
urethral ducts. It is well worth the time spent to show 
these patients how to use the inserts. There are two 
methods I have found helpful. One method is to put a 
mirror on a stool, have the woman put one leg up on 
it, and looking into the mirror, guide the suppository 
into her urethra. She should then lie down and put 
her legs tightly together for 20 to 30 minutes. The 
other method is best for supple individuals who can 
sit upright, put a mirror between their legs, and then 
guide the suppository into the urethra . 
Another means of treating the syndrome is by 
urethral dilatation in selected patients . The rationale 
behind this is that the procedure opens the para-
urethral and suburethral ducts and promotes drain-
age from the underlying glands as well as stretches 
the urethral meatus to promote a more rapid flow of 
urine. This procedure is best used in combination 
with the urethral inserts . 
Finally, there are a number of surgical methods 
*Unfortunately, Furacin inserts have just been removed from 
the market. An acceptable substitute is Protargol Urethral suppos-
itories ( 17%) which can be made-to-order in pharmacies. 
for treating this condition such as unroofing the sub-
urethral and paraurethral ducts and fulgurating 
them. 
URETHRITIS AND PROSTATITIS IN THE MALE 
Urethritis is probably the single most common 
urological problem bringing men to the primary care 
physician or the urologist. It is defined as inflamma-
tion , with or without infection, of any portion of the 
urethra and is broken down into specific and non-
specific varieties. 
Urethritis is very much more common than 
chronic prostatitis or prostatostasis with which it is 
often confused. This confusion between urethritis 
and prostatitis is not surprising in view of the ana-
tomical relationship between the urethra and the 
prostate. The numerous ducts connecting the poste-
rior urethra with the underlying prostate gland allow 
for a great similarity of symptoms of infection or 
inflammation between the two . 
Causes 
The etiology of urethritis is almost invariably 
that of sexual contact. It can be by conventional or 
anal intercourse, or, often , fellatio . Since it is well 
known that bacteria in the mouth can be more viru-
lent than bacteria in the vagina or the anus, fellatio as 
a source of urethritis should always be kept in mind 
and the patient should be asked about the nature of 
his sexual contact. 
There are a number of bacterial causes of ure-
thritis. Specific urethritis is caused by the gonococcus 
organism. It affects the anterior portion of the ure-
thra initially but will usually involve the posterior 
portion if left untreated. Mycoplasma, Trichomonas 
vaginalis, and Candida are causes of nonspecific ure-
thritis, as are viruses, gram-positive organisms, and 
some others. Bacterial infections usually affect the 
posterior portion of the urethra. 
The most common non bacterial cause of inflam-
mation is urethral "stripping." The affected patient 
does this every time he urinates and as many times in 
between voidings as privacy will allow. He takes out 
his penis, milks it out proximal to distal , and turns it 
up to look at the meatus to see if there is still some 
discharge. The urethral mucosa is almost as sensitive 
as the conjunctiva of the eye and if a urethra is 
traumatized by this vigorous stripping, a minimal 
discharge will often be produced, particularly in a 
urethra that has had recent infection in it. It is there-
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fore very important to discourage patients from this 
practice. 
Another much less common cause of urethritis is 
persistently alkaline urine. A certain number of pa-
tients seem to have urine that has a ph of 6.8 or 
higher. It may be that such patients consume large 
quantities of citrus juice which is metabolized to bi-
carbonate and produces an alkaline urine, or it may 
be for other reasons. In any case, during the act of 
voiding, the calcium phosphate crystals, which are 
precipitated out of solution because of the high ph, 
act as irritants to the urethra and continue to irritate 
it until the next voiding. 
Symptoms 
The symptoms of anterior gonococcal urethritis 
include a copious urethral discharge that ranges from 
green to yellow in color; it may at times be whitish . It 
is usually accompanied by burning on voiding and a 
feeling of discomfort in the penile or anterior urethra. 
Rarely, there may be minimal or no urethral dis-
charge. The symptoms of posterior or nonspecific 
urethritis are virtually the same as chronic prostatitis 
or prostatostasis. They consist of an itching or burn-
ing "inside" or at the base of the penis; discomfort or 
itching in the urethra on voiding; and most common, 
a minimal, clear mucoid urethral discharge on arising 
in the morning, or a 2 to 3 cm brownish or yellowish 
stain inside the patient's shorts that is seen at night. 
Diagnosis and Treatment 
The technique of three-glass urine collection in 
conjunction with pros ta tic massage and/ or the post-
prostatic massage fourth-glass specimen is used for 
determining the anatomical source of urethral infec-
tion and more specifically for separating chronic 
prostatitis from nonspecific urethritis. A three-glass 
urine specimen is first obtained, then the patient is 
asked to hold his urethra tightly shut while the physi-
cian massages the prostate vigorously. After the pros-
tatic massage, the patient is asked to release his ure-
thra and a few drops of prostatic secretions will 
usually come out into the culture tube or onto a slide. 
If no secretions are obtained, the patient should void 
a few cc of urine into a fourth glass and this will 
contain the prostatic secretions. The specimens in the 
first, second, and third glasses are then cultured as 
are the prostatic secretions or the fourth-glass speci-
men. If the first and/ or third-glass urine has more 
bacteria colonies than the prostatic secretions or the 
post-prostatic massage fourth-glass specimen, the in-
fection is in the urethra. If the opposite is true, the 
infection is in the prostate. Bacterial colony counts 
from the urethra and prostate range from several 
hundred per cc up to a few thousand per cc. When 
these studies are carried out, it will be seen that true 
bacterial infection of the prostate gland is uncom-
mon. There is, however, a condition called pro-
statostasis which occurs more frequently, but not, in 
my opinion, nearly as frequently as posterior urethri-
tis. Prostatostasis can develop when a man goes from 
feast to famine sexually. The prostatic fluid is made 
continuously in abundant supply and when there is 
no ejaculation, the prostate gland enlarges and pro-
duces the symptoms already noted in conjunction 
with nonspecific posterior urethritis. The patient 
should be encouraged to masturbate frequently, and/ 
or to have intercourse to relieve this condition. Both 
work equally well as does prostatic massage, al-
though the latter is the least favored therapy. 
For specific, or gonococcal, urethritis, a culture 
can be obtained from the discharge and, in the rare 
patient without discharge, from swabbing the distal 
urethra. The culture has to be made under increased 
C02 tension on a Thayer-Martin medium. It is best to 
do a smear and see gram-negative intracellular diplo-
cocci for the provisional diagnosis, but the culture 
should confirm it finally. The treatment of choice for 
gonococcal urethritis is aqueous procaine penicillin 
G with probenecid; alternative treatment is ampicillin 
with probenecid. For patients who are allergic to the 
penicillin group of drugs, spectinomycin and tetracy-
cline are acceptable alternatives. 
The mycoplasma organisms found with some 
cases of nonspecific urethritis can be confusing be-
cause these organisms have been reported in asymp-
tomatic as well as symptomatic individuals. The or-
ganisms are cultured with a urethral swab or using 
the urine sediment, and the mycoplasma organisms 
are identified morphologically and by specific bio-
chemical and bacteriologic tests. Patients with this 
infection are treated with one of the tetracycline 
group of drugs, although probably no more than 60% 
to 70% are cured by the medication. 
Trichomonas vaginalis is not, in my experience, 
a common cause of urethritis in the male. However, it 
should be considered a possibility particularly if the 
consort has a trichomonas infection. The organism is 
seen either on a wet mount of the urine specimen or 
in urethral discharge. This infection is best treated 
with metronidazole (Flagyl®). 
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For those patients . with inflammatory and non-
organism causes of urethritis, treatment is relatively 
simple. The rare individuals with persistently alkaline 
urine can be successfully treated with ascorbic acid 
for two to three days until the symptoms disappear. 
However, care should be taken not to use this means 
on patients with known uric acid or cystine lithiasis. 
Inflammation due to urethral stripping can be cured 
by counseling the patient to refrain from this activity. 
The most important point in treating patients 
with nonspecific urethritis is to reassure them that 
these infections are self-limited, not serious, and will 
not lead to impotency, sterility, prostatic hyperplasia,_ 
or prostatic cancer. 
Appropriate Antibiotic Therapy for Urinary 
Tract Infections 
SHELDON M. MARKOWITZ, M.D. 
Division of Infectious Diseases, Department of Medicine, M edica/ College of Virginia, Health Sciences Division of 
Virginia Commonwealth University, Richmond, Virginia 
It was stated years ago that physicians pour 
medicines about which they know little, for diseases 
about which they know less, into human beings about 
whom they know nothing.' Although as a prophet 
this wag may have overstated the case as it concerns 
the therapy of urinary tract infections (UTI), the 
character of contemporary infectious diseases is, in 
part, due to the use and abuse of anti-infective 
agents. 2•3 One has only to look at the rising incidence 
of gram-negative bacteremia and the emergence of 
multiple antibiotic-resistant organisms over the past 
several decades to appreciate the impact physicians 
have made with these agents.4·5 Despite the draw-
backs, the benefits resulting from the use of antibiot-
ics far outweigh the deleterious effects, a fact perhaps 
realized most vividly by physicians whose careers 
reach back to the pre-chemotherapeutic era. The en-
thusiasm for antibiotics makes them one of the most 
prescribed groups of drugs in the United States, ac-
counting for 15% to 20% of all new and refill pre-
scriptions .6 Undoubtedly many of the prescriptions 
are used to treat persons with UTis, in light of the 
fact that UT!s are said to rank second only to upper 
respiratory infections as the most common infections 
in the western hemisphere.7 
Principles of Therapy 
Without belaboring the point, how does the phy-
sician steer his way through the many antibiotics 
Correspondence and reprint requests to Dr. Sheldon M. 
Markowitz, Box 92, Medical College of Virginia, Richmond, Vir-
ginia 23298. 
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which are promoted so vigorously by pharmaceutical 
companies, perhaps in response to the competitive 
pressures and potential profits of what has become a 
multi-billion dollar industry? Certain characteristics 
are desirable in any antibiotic, and it behooves the 
physician to consider these characteristics when eval-
uating the potential usefulness of the agent.8 
1. Activity. An agent with bactericidal activity 
against a wide spectrum of microorganisms, and one 
that doesn't disturb normal flora or lead to the emer-
gence of resistant organisms should be sought. 
2. Toxicity. Adverse reactions should be infre-
quent, and teratogenicity absent. 
3. Pharmacology. Pharmacologic properties should 
be such that adequate concentrations of the drug are 
achieved and maintained near the organism for pro-
longed periods. 
4. Physicochemica/ properties. The drug should 
be stable (dry or in solution) tolerant of pH changes, 
and readily absorbable from the gastrointestinal (GI) 
tract. 
5. Interactions . The drug should not interact with 
other therapeutic agents. 
6. Cost . The agent should be inexpensive and 
hence available to all who need it. 
Of course, no such "magic bullet" exists, and 
because it doesn't , one should be guided, when treat-
ing UTis, by certain fundamental principles.9 
I . The presence of a bacterial infection should be 
established . Symptoms alone are not sufficient evi-
dence for the diagnosis of UTI, as up to 50% of 
women with dysuria and frequency have sterile 
urine. 10 The finding of one or more bacteria per oil 
field in a Gram stain of uncentrifuged urine correlates 
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well (over 90%) with the presence of 100,000 orga-
nisms or more per ml of urine. Numbers of this 
magnitude usually indicate true infection (significant 
bacteriuria) and not procurement contamination 
with gram-negative enteric bacilli. In an asympto-
matic person, three consecutive daily urine cultures 
obtained by the clean-voided method and each con-
taining 100,000 organisms per ml of the same bacte-
rium indicate that the patient has at least a 95% 
chance of having a UTI.11 In a symptomatic person, 
bacteria seen on microscopic examination and one 
urine culture containing 100,000 organisms or more 
per ml carries the same 95% probability of true in-
fection. 
2. The elimination of bacteriuria requires the use 
of antibiotics which are active against the common 
urinary pathogens and which achieve inhibitory con-
centrations in the urine, not the serum. Dis-
appearance of bacteriuria correlates well with the 
sensitivity of the organism to achievable urinary lev-
els.12·13 This serves to underline the obvious dis-
crepancies sometimes seen between antibiotic sensi-
tivities in vitro and the eradication of bacteriuria. 
3. Underlying urinary tract abnormalities, par-
ticularly obstructive or neurogenic lesions, should be 
corrected if possible; obstruction from whatever 
cause not only has a compromising effect on renal 
function but it also practically eliminates the likeli-
hood of successful antibiotic therapy. 
4. The hallmark for the eradication of infection 
is the absence of bacteriuria following the cessation 
of therapy. Symptomatic improvement is a poor in-
dicator of successful therapy because symptoms may 
improve with only the slightest suppression of bacte-
riuria. In addition, while bacteriuria may disappear 
during therapy, recurrence of the original organism 
(see below) is common and can be detected only by 
obtaining cultures after the completion of therapy. 
5. Prolonged follow-up is required to insure per-
manent cure of the UT!. Recurrence of an initially 
symptomatic and apparently successfully treated in-
fection may be asymptomatic, and constant vigilance 
by the physician can pay dividends in reduced mor-
bidity from UTis. This is done usually by obtaining 
periodic urine cultures (Figure). A culture obtained 
between 48 to 72 hours after the initiation of therapy 
should be sterile. If it is not, then the therapy should 
be recognized as a failure and the patient should be 
treated with an appropriate antibiotic chosen on the 
basis of sensitivity tests. If the culture is negative, 
additional cultures should be obtained one to two 
weeks following completion of therapy, monthly for 
three months, then at three-month intervals for one 
to I 1/2 years. The patient should be considered cured 
if there is no recurrence during the period of observa-
tion. 
Therapeutic Agents 
The goal of therapy for UT!s is the elimination 
of bacteriuria and the most effective way of achieving 
this is with antibiotic therapy. The antimicrobial 
agents frequently used to treat UT!s are listed in the 
Table. Most share the common characteristics of 
being active against the majority of common urinary 
tract pathogens and being excreted at high concentra-
tions into the urine. 
Sulfonamides. The sulfonamides were the first 
group of agents shown to be consistently useful for 
treating UT!s. Many effective sulfonamides are avail-
able, but the short-acting, oral nonabsorbable drugs, 
such as sulfisoxazole and sulfamethoxazole, are gen-
erally recommended. These agents achieve high uri-
nary concentrations and are soluble at an acid pH. 
Toxicity is relatively infrequent. They are especially 
effective against Escherichia coli and Proteus mirabilis 
but generally are useful only for the first few episodes 
of infection because of the emergence of resistant 
bacteria. Although sulfonamides offer no real advan-
tage over other agents, they are inexpensive (see 
Table) and hence available to most patients. Sulfona-
mides should not be used in persons with glucose-6-
phosphate dehydrogenase deficiency, in pregnant 
women near term, and in newborn infants because of 
the danger of producing kernicterus in the neonate. 
Penicillins. Among the penicillins, ampicillin re-
mains the drug of choice for UTis. It is effective 
against many gram-positive and gram-negative orga-
nisms and reaches adequate levels in the renal me-
dulla. Ampicillin is the preferred agent for pregnant 
women and newborns, and is especially useful in 
treating UT!s due to susceptible organisms in pa-
tients .with renal insufficiency. There is no evidence to 
indicate that ampicillin is superior to sulfonamides in 
the management of uncomplicated UT!s (see below), 
just as there is no evidence to indicate that newer 
penicillin derivatives, such as amoxicillin, are supe-
rior to ampicillin. Diarrhea is frequent and rashes 
occur in 5% to 10% of patients.1 
Tetracyclines. The tetracyclines have been rele-
gated to a less prominent role in the treatment of 
UT!s. The best urinary levels are achieved with tet-
racycline and oxytetracycline.11 Newer derivatives, 
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Acute 
Symptoms* 
! 
culture urine and 
begin therapy 
Reinfection 
~ 
Culture urine 
+ 
Asymptomatic 
bacteriuria* 
! 
2 consecutive cultures 
with same organism 
precedes therapy 
If bacteriological and/or 
clinical response, treat 
for 10-14 days 
Relapse 
~ 
Negative 
cultures 
Retreat with appropriate Consider therapy l drug 10-14 days for 6 weeks 
CURE 
If frequent, 
consider long 
term prophylaxist 
Reinfection 
If occassional treat 
each episode for 
10-14 days 
Relapse 
l 
Consider therapy 
for 6-12 months 
CURE 
CURE 
* Radiographic evaluation should be obtained on all children, 
all men, young women, and probably in all patients with 
bacteremia 
t Not in asymptomatic elderly without obstruction 
Figure-Diagrammatic approach to the management of urinary tract infections. 
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TABLE 
Antibiotics Useful in the Therapy of Urinary Tract Infections in Adults 
Antibiotic Tradename(s) 
Oral: 
Sulfisoxazole Gantrisin 
Sulfamethoxazole Gantanol 
Penicillin G Many 
Ampicillin Many 
Amoxicillin Larotid , Amoxil 
T etracycline Many 
Cephradine Velosef, Anspor 
Cephalexin Ke flex 
Nitrofurantoin Furadantin 
Macrodantin 
Nalidixic acid NegGram 
Trimethoprim-Sulfamethoxazole Bactrim , Septra 
Parenteral: 
Ampicillin Many 
Carbenicillin Geopen , Pyopen 
Cephalothin Ke ft in 
Cefazolin Ancef, Kefzol 
Gentamicin Garamycin 
Amikacin Amikin 
Dosage• 
0 .5-1.0 gm q 4-6 h 
l.Ogm q 8-12 h 
0.4-0.8 X I 0'µ q 6 h 
0.5-1.0 gm q 6 h 
0.25-0.5 gm q 8 h 
0.25-0.5 gm q 6 h 
0.5gm q 6 h 
0.5gm q 6 h 
0.05-0. 1 gm q 6 h 
0.05-0. I gm q 6 h 
0:5-1.0 gm q 6 h 
2 tablets q 12 h 
0.5-2 gm q 4-6 h 
1-5 gm q 4-6 h 
0.5-2 gm q 4-6 h 
0.5-1.5 gm q 6-8 h 
1-1.7 mg/ kg q 8 h 
5 mg/ kg q 8 h 
Cost in dollars (dose)b 
.04 (0 .5 gm) 
.08 (0.5 gm) 
.01 (0.2 X IO'µ) 
.09 (0.5 gm) 
.30(0.5gm) 
.03 (0.5 gm) 
.56 (0.5 gm) 
.52 (0.5 gm) 
.01 (0.05 gm) 
.15(0.05gm) 
.12 (0.5 gm) 
.21 (per tablet) 
1.11 (I gm) 
2.20(1 gm) 
2.75 (I gm) 
5.05 (I gm) 
5.05 (per 80 mg vial) 
4 .93 (per JOO mg) 
• Usual average or range of dosages in patients with normal renal function. 
b Cost to pharmacist based on listings in the American Druggist Blue Book (Hearst Corp. Publishers), October 1977. 
such as doxycycline and minocycline, a lthough ap-
proved for use in UTis, have significant extrarenal 
routes of excretion, so that the low urinary concen-
tration achieved makes them Jess desirable for ther-
apy.14 Generic tetracycline is inexpensive (see Table). 
Resistance to tetracycline emerges rapidly during 
therapy; however, tetracyclines are probably as effec-
tive as the- sulfonamides and ampicillin for treating 
uncomplicated UTis (see below). Fulminant hepatitis 
has been induced in those receiving large parenteral 
doses of tetracycline (greater than 2 gm per day), and 
irreversible discoloration and maldevelopment of 
permanent teeth is a danger in children under age 8 
who receive these drugs 14; however, GI signs and 
symptoms are the most common side effects of ther-
apy.14 
Cephalosporins. The instances where ceph-
alosporin antibiotics should be used are difficult to 
define, but they are indicated possibly for treating 
gram-positive coccal infections (except those caused 
by enterococci and methicillin-resistant staphylo-
cocci) in patients allergic to penicillin. These agents 
are useful in treating infections due to Klebsiella 
pneumoniae and antibiotic strains of E coli, P mira-
bilis, and other gram-negative bacilli. The use of 
cephalosporin antibiotics for central nervous system 
infections is contraindicated. 15 Although most of 
these drugs achieve good urinary levels, and are 
therefore effective agents for the therapy of UTis, 
most are expensive (see Table) and should not be 
used when cheaper, equally effective drugs are avail-
able. The two most important oral agents, cephalexin 
and cephradine, are simi lar and can be used inter-
changeably.16 Up to 5% of patients develop allergic 
reactions such as rash, fever, and, rarely, anaphy-
Jaxis11; 5% to 15% of penicillin-allergic patients will 
manifest allergy to the cephalosporins. 18 
Aminoglycosides. The aminoglycoside antibiotics 
are parenterally administered agents useful against a 
wide variety of gram-negative organisms. These 
drugs have the potential for causing significant oto-
and nephrotoxicity1• and should therefore be reserved 
for therapy of hospitalized patients with moderate to 
severe UTis caused by organisms resistant to Jess 
toxic agents. Dosage should be adjusted for those 
with renal insufficiency; such alterations in dosage 
can be achieved by any of several published pro-
grams.20- 22 Gentamicin and amikacin are two com-
monly used aminoglycoside antibiotics which differ 
little in the incidence of toxicity. 23 However, amikacin 
is resistant to many more of the aminoglycoside-
inactivating enzymes than gentamicin,24 therefore its 
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greatest utility at present is in the therapy of UTis 
caused by gentamicin-resistant organisms. 
Nitrofurantoin. This drug is available in crystal-
line and macrocrystalline forms. The latter com-
pound is absorbed from the GI tract and excreted 
more slowly than the crystalline form and allegedly 
causes less GI upset. Nitrofurantoin achieves high 
urine concentrations and is more active at an acid 
pH . It is effective against gram-positive and gram-
negative organisms except Pseudomonas sp, some En-
terobacter sp, Serratia marcescens, and indole-posi-
tive Proteus. The drug may be useful for lower and 
upper UTI. 11 Nitrofurantoin is contraindicated for 
use in patients with renal failure because little of the 
drug is found in the urine and because the incidence 
of irreversible peripheral neuropathy is increased un-
der these circumstances. 11 Small amounts of this 
orally administered drug is found in the feces, which 
probably accounts for the relatively low incidence of 
resistant enteric organisms emerging during and after 
therapy. Thus, nitrofurantoin would appear to be a 
useful therapeutic and prophylactic agent for patients 
with recurrent UT1s25 (see below). 
Nalidixic acid. Nalidixic acid and its cogener, 
oxolinic acid, are oral antimicrobials which have vir-
tually the same antibacterial spectrum, including 
most gram-negative urinary tract pathogens except 
for Pseudomonas sp, Serratia marcescens and indole-
positive Proteus. Resistance develops rapidly and re-
currence of infection with resistant organisms is not 
uncommon. Blood and, presumably, tissue levels 
are low. These agents are moderately expensive (see 
Table) and should be used as alternative therapy to 
other oral agents such as the sulfonamides and ampi-
cillin. 
Methenamine salts. Methenamine salts have a 
limited role in the therapy of UTis. These agents are 
effective against most gram-negative organisms in 
vitro, but require an acid medium (pH of 6 or less) 
for release from methenamine of the bactericidal 
agent formaldehyde; tissue levels are low to absent. 
The main uses are for suppression of bacteriuria or 
prophylaxis between episodes of infection. The effi-
cacy of methenamine salts in patients with chronic in-
dwelling bladder catheters recently has been ques-
tioned.26 
Trimethoprim-sulfamethoxazole (TM P-SMX ). 
TMP-SMX is a fixed combination of drugs which 
acts additively or synergistically against a wide range 
of gram-positive (including enterococci) and gram-
negative organisms, except Pseudomonas and Alcali-
genes sp. The list of indications for TMP-SMX con-
tinues to grow and presently includes infections due 
to Shigella sp, Salmonella typhi, ampicillin-resistant 
Haemophilus infiuenzae, and Pneumocystis carinii, 
and diseases such as acute exacerbations of chronic 
bronchitis, acute otitis media, and gonococcal ure-
thritis.27 Its most practical applications are the treat-
ment of and prophylaxis for recurrent UTis caused 
by susceptible organisms.25 Emergence of resistant 
organisms in the fecal flora has not been a major 
problem and because trimethoprim penetrates pros-
tatic tissue, TMP-SMX is probably the drug of choice 
for recurrent or chronic prostatic infection.28 The 
adverse effects of TMP-SMX represent the sum of 
reactions to trimethoprim (folate deficiency syn-
dromes and possible teratogenic effects) and sulfame-
thoxazole (see above). The drug may be used in mild-
to-moderate renal failure. 29 
Urinary Tract Infections 
Urinary tract infections represent a broad group 
of clinical entities with bacteriuria as the common 
thread . Many classifications are possible, but those 
which include not only the type of infection but also 
the site of involvement allow for the most accurate 
assessment of antibiotic therapy. Although the site of 
infection in many instances is unknown, enough evi-
dence is available to analyze antibiotic therapy in the 
following clinical categories of UTI: acute uncompli-
cated UTI; recurrent UTI ; complicated UTI; asymp-
tomatic bacteriuria; and catheter-related UTI. 
A cute uncomplicated UT/s usually represent the 
first or second infection in young sexually active 
women without underlying urinary tract abnormal-
ities, and are caused by antibiotic enteric bacilli (most 
commonly E coli) which emanate from antibiotic 
fecal flora . This type of infection responds well to 
practically all commonly used oral antibiotics, but 
because they are effective, inexpensive, and well-tol-
erated, the oral, nonabsorbable sulfonamides remain 
the therapy of choice. Treatment is usually given for 7 
to 14 days . Longer courses of therapy are usually not 
necessary. Many alternative agents exist (see Table), 
but none have proven superior to the sulfonamides 
and most are more expensive. In the absence of an 
obstructive or neurogenic lesion , the urine should be 
sterile between 48 to 72 hours (Figure). If bacteriuria 
persists, therapy should be guided by the results of 
sensitivity testing. 
Some patients with acute symptomatic infection 
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fail to respond to the initial antibiotic therapy or 
suffer recurrence of the infection. The recurrence may 
be a relapse of the initial infection with the same 
pathogen, suggesting a parenchymal focus of infec-
tion in the kidney or prostate or may be caused by 
different organisms, so-called reinfections. The source 
for reinfection is almost always the bowel flora. Ap-
proximately 80% of recurrences are reinfections and 
most are limited to the bladder. Antibiotic sensitivity 
testing assumes added importance in this situation 
because the pathogen will probably not be sensitive 
to sulfonamides if used initially. Ampicillin, tetracy-
clines, cephalosporins, and TMP-SMX are preferred 
and are given orally for I 0 to 14 days. Each course of 
therapy will result in a 20% to 25% long-term cure 
rate. 11 Those having a second or third episode of 
infection should probably be evaluated urologically 
or radiographically (see Figure) . Those with occa-
sional recurrences (three or less per year) can be 
treated like acute uncomplicated infection. With 
more frequent recurrences, especially in the absence 
of urological abnormalities, the precise duration of 
therapy is not well established. Closely spaced recur-
rences are likely to be due to relapse and some have 
suggested treating true relapses for six weeks to one 
year. 10 Most authorities suggest six weeks of therapy 
with the realization that the optimal duration of ther-
apy for this group of patients is controversial. An 
alternative approach consists of intensive initia l treat-
ment for IO to 14 days, followed by daily low-dose 
nitrofurantoin (100 mg) or TMP-SMX (one half to 
one tablet). Prophylaxis should be continued for up 
to six months, then discontinued, and the patient 
observed. 
A cute complicated UT ls are a third category of 
infections; they are almost always associated with 
underlying genitourinary tract or neurological dis-
orders. Isolated organisms tend to be multiply 
drug-resistant. Permanent eradication of the bac-
teriuria is unlikely, but the goal is to control symp-
toms. Initia l therapy ideally should be based on 
sensitivity studies, but pending culture results, an 
aminoglycoside antibiotic, that is, gentamicin, is an 
obvious choice. Therapy for I 0 to 14 days is usually 
adequate. Emergence of resistant organisms in this 
setting is a probable event. 
Asymptomatic bacteriuria represents a large 
group of UTis with an incidence ranging from 1.2% 
in pre-school girls to over 15% in women over age 
60. 11 Certain groups are known to be at risk for 
acquiring significant asymptomatic bacteriuria and 
subsequent symptomatic UTI. Included are pregnant 
women in the first trimester, women with diabetes, 
preschool- and school-age girls, and those with a 
previous history of urinary tract instrumentation . 
About 5% of pregnant women will have asympto-
matic bacteriuria at the first prenatal visit and 20% to 
40% of these will develop acute pyelonephritis.9 As-
suming that acute renal infection in the mother con-
tributes to prematurity and fetal mortality, treatment 
should be initiated. The preferred agents are the pen-
icillins, cephalosporins, nitrofurantoin, and short-
acting sulfonamides (first trimester only). Treatment 
will eliminate bacteriuria in 80% of these patients. 
Some will have recurrence and for these patients, 
nightly prophylaxis through term with nitrofurantoin 
is recommended. The necessity to treat other groups 
of patients with asymptomatic bacteriuria is less cer-
tain, especially elderly women in whom bacteriuria 
tends to be recurrent even in the absence of under-
lying disease. Available evidence indicates that, in 
adults, progressive renal damage due to UTI is an 
uncommon occurrence in the absence of obstruc-
tion .10 Several attempts at eradication seem worth-
while. If bacteriuria recurs, genitourinary evaluation 
is warranted. If no abnormalities are found, no fur-
ther therapy is necessary in the elderly. 
Catheter-related infections are the most common 
hospital-acquired infections and the most frequent 
causes of gram-negative bacteremia.•·11 Patients ac-
quiring bacteriuria with short-term closed drainage 
should be treated with an effective antibiotic for 7 to 
IO days after the catheter is removed . Long-term 
drainage represents a different problem. Patients on 
long-term drainage are continuously infected but 
usually do well. Antibiotics will not clear bacteriuria 
permanently while the catheter remains in place. 
Therapy is reserved for acute episodes of infection . 
A scheme for the management of patients with 
bacteriuria is given in the accompanying Figure. It is 
meant to serve only as a guide for the practicing 
physician and should be modified in light of future 
improvements in the diagnosis, localization, and 
therapy of UTis. Optimal therapy awaits a more 
precise classification of UTis, the end result of which 
will be a reduction in morbidity and mortality from 
UTis, and a significant decrease in the cost of related 
health care. 
The figure is reproduced with permission from Urinary Tract 
Infection and Its Management, Donald Kaye (ed). 
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Intrascrotal Masses: Differentiation, 
Diagnosis, and Management 
STEPHEN N . ROUS, M.D. 
Professor and Chairman, Department of Urology, Medical University of South Carolina, Charleston, South 
Carolina 
The differentiation of scrotal masses consists of 
combining the basic principles of physical examina-
tion, particula rly inspection and palpation, with an 
This is an a bstract of the lecture given by Dr. Ro us a t the 
49th Annual McG uire Lecture Series, December 3, 1977, at the 
Medica l College of Virginia, Richmo nd, Virginia . 
A limited supply of book lets by Dr. Stephen N. Rous 
entitled, "Intra-Scrota l Problems with Particular Reference to Pa l-
patory Findi ngs," may be obtained fro m him, as long as they 
remai n avail ab le, through the Department of Urology, M edical 
U ni versity of South Carolina, C ha rlesto n, SC 29403. 
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exact knowledge of the anatomy and pathology of the 
scrotum and its contents. The correct diagnosis of 
each of the nine common scrota l masses-epididy-
mitis·, epididymo-orchitis, torsion of the spermatic 
cord, hydrocele, scrotal hernia, spermatocele, vari-
cocele, hematocele, and cancer of the testis-deter-
mines the treatment to be used, which can range from 
masterly inactivity to surgical intervention. Obvi-
ously, experience plays its part a nd the opportunity 
to examine scrotal masses should be an integral part 
of the education of the primary physician. 
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Common Pediatric Problems: Hypospadias, 
Enuresis, and Circumcision 
JOHN H. TEXTER, JR., M .D. 
Associate Professor, Division of Urology, Department of Surgery, Medical College of Virginia, Health Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
Three topics of common pediatric interest from 
the urologist's viewpoint are congenital hypospadias, 
persistent enuresis, and complications of elective cir-
cumcision. None of these are usually life-threatening 
in severity, yet each problem can be of profound 
psychological importance and play an extremely im-
portant role in the child's subsequent development. 
The least common of the three is a malformation 
or incomplete formation of the male urethra and the 
associated deformity of the foreskin and penile shaft 
known as hypospadias. This condition results from 
incomplete closure of the urethra in utero . Since the 
urethra normally begins closing from the proximal 
end of the penile shaft and progresses distally to the 
glans, it is possible for the hypospadiac meatus to be 
positioned at any location from the perineum to the 
coronal sulcus. The timing of the arrest of the ure-
thral closure will determine the location of the 
meatus and the length of the deficient distal urethra. 
Since the portion of the urethra which is not closed is 
represented by fibrous tissue or what was destined to 
be normal corpus spongiosum, this material is non-
elastic and is represented by a fibrous band or tract. 
When erection occurs, this tissue pulls down on the 
penile shaft and produces the curvature of the penis 
or ventral chordee seen in classical hypospadias . The 
urethral closure is also responsible for the formation 
Thi s is a n edited transc ript of the lecture given by Dr. Texter 
at the 49th Annual McGuire Lecture Series, December 3, 1977, at 
the Medical College of Virginia, Richmond, Virginia. 
Correspo ndence and reprint requests to Dr. John H . Texter, 
Division o f Uro logy, Box 176, Medical College of Virginia, Rich-
mond , VA 23298. · 
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of the normal prepuce. When hypospadias occurs, 
the foreskin is incomplete ventrally, producing the 
typical "dorsal hood" of preputial tissue seen in this 
condition . 
Over the years, numerous types of surgery have 
been recommended to correct this malady. Often 
these procedures were only partially successful, and 
individual surgeons developed their own modifica-
tions of previously described techniques . A very ef-
fective method was used about 200 BC by the Greeks, 
Helidous and Antius. They simply guillotined the 
distal end of the penis at the level of the meatus. In 
this maneuver, all three deformities were corrected; 
the curvature was gone, the dorsal hood excised, and 
the meatus was now at the end of the penis. The 
stump end of the penis was then cauterized with a 
red-hot iron which provided hemostasis and pro-
duced a swollen, knotty stub at the end of the penis 
which occasionally resembled a glans penis . There 
were also very few readmissions or requests for repeat 
surgery. 
Surgical techniques improved over the centuries. 
In 1842, one of the first successful, planned hypo-
spadias repairs was performed by Dr. John Peter 
Mettauer in the western part of Virginia. With pres-
ent-day techniques it is possible to completely repair 
even the most severe degree of hypospadias and, 
when healing is complete, to have a relatively normal-
appearing penis capable of normal micturition and 
sexual function. 
While the multitude of surgical repairs will not 
be individually discussed, most severe degrees of hy-
pospadias require corrective surgery performed in 
stages. This often results in a child returning to the 
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operating room at regular intervals over a period of 
several years. This is undesirable from a financial as 
well as a psychological standpoint. Fortunately, in 
the mid-1950s, single-stage repairs became possible; 
this not only decreased the psychological stresses on 
the patient and family, but also produced excellent 
cosmetic results. The tube graft repair for hypo-
spadias was popularized by Ors. Devine and Horton 
in Norfolk, Virginia. While the original technique has 
been altered somewhat, the basic procedure is sound 
and continues to produce excellent results in the 
hands of many surgeons throughout the world. In the 
late 1960s, the single-stage "flap" procedure was de-
vised by Dr. Norman Hodgson which added another 
useful tool to the urologist's armamentarium. 
These new methods have changed our concept of 
what is considered a satisfactory repair. In 1950, Dr. 
Campbell's textbook, Urology, stated that if the hy-
pospadias were mild and the meatus were located in 
the distal part of the penile shaft, no attempt should 
be made to correct the condition. If the patient had 
"free urination and adequate insemination," any fur-
ther surgical repair was "meddlesome"; however, to-
day there is concern about the cosmetic appearance 
as well as the functional capabilities of the penis. If 
the chordee is mild and the meatus located distally, it 
may still be desirable to correct these conditions and 
position a new meatus on the tip of the glans penis. 
This is now possible, using one of the new single-
stage procedures; however, since both types of repair 
require the use of excess skin which ideally can be 
taken from the foreskin or dorsal hood, it is ex-
tremely important not to circumsize the child. If there 
is any question about the possibility of subsequent 
surgical correction at the time of birth, circumcision 
should be postponed. 
Enuresis 
The second pediatric problem the urologist is 
often asked to evaluate is far more common than 
hypospadias. This is the problem of the persistent 
bed-wetter. This problem is not unique to our coun-
try, but occurs throughout the world. It is interesting, 
however, to note that the frequency differs greatly 
from one country to another. For example, in the 
United States there is an incidence of enuresis at age 5 
of about 15% to 20%, whereas in Brazil the incidence 
in this age group is close to 2%. This suggests that 
social and environmental factors contribute to enu-
resis. With increasing age, enuresis generally becomes 
less common so that in our country by age 10, only 
5% of the children are enuretic and by age 15, only 
1 %. The reported incidence of 2% enuresis in military 
recruits must be viewed carefully as the individual 
may be influenced by the fact that bed-wetting is o'ne 
of the criteria for military rejection. On the basis of 
these statistics, it is valid for the family physician to 
recommend to the family that treatment for enuresis 
is not always necessary and if given enough time the 
bladder will "mature and the child will outgrow his 
or her bed-wetting." 
Until the age of 3 years, enuresis or daytime 
wetting is physiological and probably the result of 
incomplete myelinization of the innervation. The age 
of 3 years is purely an arbitrary cutoff point, but most 
authorities agree that beyond this point, enuresis 
should be considered to be either functional or or-
ganic. The majority of these enuretic children will 
demonstrate a functionally decreased bladder capac-
ity; however, under general anesthesia the bladder 
volumes are within normal limits. In general, if the 
wetting occurs only at night and there are no other 
urologic symptoms, little is to be gained by doing an 
extensive urologic evaluation. This impression is 
borne out by the study of Dr. Tony Middleton of Salt 
Lake City who studied the results of 216 enuretic 
children who were completely evaluated and had only 
enuresis. He concluded that the likelihood of identi-
fying any major urologic abnormality was nil, al-
though, if there were other symptoms or findings 
such as urinary tract infection, diurnal enuresis, or 
difficulty with urination, base line urologic evaluation 
was helpful. According to this study, approximately 
10% of the children required some type of surgical 
repair. 
It is interesting to note that many of these func-
tional enuretic children came from a family in which 
other members were enuretic. If both the mother and 
father had enuresis, there was an 80% chance that one 
of their children would be enuretic. Also, if the 
mother or father developed their control at age 10, 
then it was quite likely that their child would stop 
wetting the bed at about the same age. Also, an 
identical twin would be more likely to have enuresis 
than a dizygotic twin. 
There is a vast spectrum of recommendations 
concerning the treatment for essential enuresis; how-
ever, most measures fall into one of three main cate-
gories. 
1. Bladder training maneuvers and fluid restric-
tion: Effort is directed to keep records of voiding 
times and the volumes passed with each voiding. The 
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patient is aroused during the middle of the night and 
required to empty his bladder in order to keep the 
bladder as empty as possible. Also, the youngster is 
not allowed to drink any additional liquids, following 
a set time of day such as after the evening meal or 
before bedtime. 
2. Drug therapy: Antispasmodics such as bella-
donna or propantheline bromide (Pro-Banthine) are 
effectively used to increase functional bladder capac-
ity. Other agents such as the tricyclic antidepressives 
are prescribed for their altered sleep patterns and 
their direct action upon bladder musculature. In the 
group of antidepressive agents, the most popular one 
at the present time is imipramine (Tofranil). 
3. Waking devices: The sleeping youngster is 
aroused from deep sleep by activation of some electri-
cal device when urine leakage occurs. The urine 
causes electrical contact to occur and completes a 
circuit which in turn sets an alarm, electrical stimuli, 
or flashing lights. The waking devices are said to be 
very popular in England and are reported to be quite 
effective in terminating enuresis. In the United States 
and Canada more emphasis has been placed upon the 
bladder training program and drug therapy. Both 
techniques are reported to be effective in 65% to 80% 
of enuretic patients. 
Circumcision 
Today, circumcision is the second most fre-
quently performed operation on the male. While it is 
often performed for religious purposes and less often 
for strict urologic indications, the largest number of 
circumcisions are done for hygiene or simply as a 
routine procedure. Dr. Julien Ansell at the University 
of Washington in Seattle evaluated all the circum-
cisions performed in the University Hospital during a 
10-year period of time. It is of note that of 5,882 male 
births, 5,521 or 94% were circumsized before they left 
the hospital. Of the remaining 361 male infants who 
were not circumsized, 22 were denied the operation 
because of some degree of hypospadias . This corre-
lates well with the reported incidence of hypospadias 
of about 1 per 267 male births. 
About half the circumcisions were done with the 
Gomco® clamp and the remaining half performed by 
the Plastibell® apparatus. The overall complication 
rate from routine elective circumcision was slightly in 
excess of 1 %. This was most often due to hemorrhage 
occurring equally often with the Gomco® clamp and 
the Plastibell®. Most bleeding problems were easily 
managed by application of an adrenaline (1-1,000) 
soaked sponge applied to the area of bleeding (25 out 
of 59 patients were successfully handled by this mea-
sure) . The others required placement of a suture or 
ligature to provide hemostasis. Infections were un-
common, occurring in less than 0.4% of patients and 
were generally managed with local measures such as 
cleaning and soaks. Only four patients, all of whom 
had Plastibell® circumcisions, required systemic anti-
biotics. Nine patients had wound-healing problems 
such as dehiscence and denudation of the penile shaft 
skin. Eight of these patients had Gomco® clamps 
used for the circumcision. In general, it was con-
cluded that circumcisions can be performed routinely 
with a low complication rate and those complications 
that do occur are relatively easy to manage. The type 
of clamp used for the operation does not appear to 
make a significant difference. 
Management of Carcinoma of the Kidney and 
Urinary Bladder 
WARREN W. KOONTZ, JR., M.D. 
Professor and Chairman, Division of Urology, Department of Surgery, Medical College of Virginia, H ea/th 
Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
CARCINOMA OF THE KIDNEY 
Tumors of the upper urinary tract constitute 1 % 
to 2% of all cancers, and each year 11,000 new cases 
are diagnosed in the United States. Approximately 
half of these patients have metastatic disease at the 
time of diagnosis. Hypernephroma, or renal cell car-
cinoma, was first described in 1863 by Grawitz. These 
tumors arise from tubular epithelial cells and are 
correctly termed renal cell carcinoma or renal cell 
adenocarcinoma. There is evidence that further iden-
tifies the cell of origin as being from the proximal 
convoluted tubular epithelium. There does not ap-
pear to be a specific racial or ethnic incidence al-
though it occurs three times more often in men than 
in women. Few epidemiological studies of this disease 
have been undertaken, although there is some associ-
ation between the use of tobacco and an increased 
incidence of renal cell carcinoma. The classical triad 
of hematuria, pain, and a palpable mass are late 
findings with a poor prognosis which occurs in 10% 
of the patients and usually represents metastatic dis-
ease. Forty percent of the patients may have hema-
turia or other urinary complaints. Local effects of the 
tumors are hematuria, pain, and a flank mass, but the 
presenting symptoms may include a varicocele in the 
male which is produced by direct pressure of the 
tumor on the spermatic vein or because of stasis 
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caused by an obstructing tumor thrombus in the vena 
cava. Systemic toxic effects such as hyperpyrexia may 
be of an intermittent or variable nature. Anemia or 
abnormal liver chemistries may also be present. 
Erythrocytosis, hypertension, and hypercalcemia 
may also be manifest. 
Once a renal mass is found, a number of proce-
dures can be followed in order to evaluate the patient 
before surgery. These include the use of intravenous 
excretory urography, retrograde pyelography, neph-
rotomography, renal angiography, and venacavo-
graphy, along with sonographic examination of renal 
masses and the evaluation of renal masses by the use 
of computerized axial tomography. 
The staging classification developed by Robeson 
is probably the most widely accepted: Stage I-tu-
mor confined within the kidney; stage 2-perirenal 
fat involvement confined within Gerota fascia; stage 
3-a. gross renal vein or inferior vena cava in-
volvement, b. lymphatic involvement, and c. vascular 
and lymphatic involvement; stage 4-a. adjacent or-
gans other than the adrenal involved, and b. distant 
metastases. Renal vein involvement without peri-
nephric involvement or lymphatic spread does not 
seem to alter the prognosis at 5-10 years where lym-
phatic involvement is an ominous sign. 
Treatment 
Surgical removal of the tumor for cure is the 
basic management of the patient with hyper-
nephroma. The single, most significant advance in 
technique and its influence on survival were pointed 
out in 1968 by Robeson, who used the combination 
of early ligation of the renal artery and vein, complete 
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removal of the perinephric envelope, and surgical 
extirpation of the lymphatic field. Caution in han-
dling of the renal vein is important, especially if there 
is tumor involvement of the veins, as portions of 
renal vein tumor may break off and cause acute pul-
monary embolization. 
Preoperative Radiation 
Several investigators have advocated the use of 
preoperative radiation in the management of renal 
cancer, but random clinical trials to date have not 
shown that this has improved long-term survival. In 
certain patients, however, a preoperative course of 
radiotherapy of 3,000-4,000 rads to the kidney in four 
weeks has markedly decreased the vascularity of the 
tumor. There is some evidence that postoperative 
radiotherapy may have a beneficial effect on survival 
statistics, especially if there has been extracapsular 
invasion and tumor has been left behind. 
Chemotherapy 
The use of chemotherapy in the management of 
metastatic renal carcinoma has proven particularly 
disappointing. Good results have been quoted by 
some investigators with the use of medroxyprogeste-
rone (Provera) 100 mg t.i.d . and a number of other 
chemotherapeutic agents singly or in combination. 
Special Management Problems 
Involvement of the renal vein and vena cava are 
of interest because of the possible use of extra-
corporal circulation in order to approach the patient 
with tumor thrombus in the renal vein, the vena cava, 
and the atrium of the heart. 
Carcinoma arising in a solitary kidney provides 
a real therapeutic dilemma. Procedures such as par-
tial nephrectomy in situ, bench surgery with the re-
moval of the kidney, perfusing the kidney for preser-
vation, surgical excision of the tumor with repair of 
the kidney and autotransplantation back into the 
patient, and total extirpation with homotransplan-
tation at a later date have all been used. 
Approximately 12% of upper urinary tract ma-
lignancies are from renal pelvic tumors. These are 
often transitional cell carcinomas, but a few are of the 
squamous cell variety. The diagnosis is usually based 
on the appearance of a filling defect on intravenous 
urography or retrograde pyelography. A differential 
diagnosis from a nonopaque stone or blood clot may 
be difficult. As these tumors tend to be multiple, the 
therapy for them is total removal of the kidney and 
renal pelvis with removal of the entire ureter and a 
cuff of bladder. For those people who have under-
gone only partial removal of the ureter, recurrence in 
the stump of ureter has been high. 
BLADDER CANCER 
Carcinoma of the urinary bladder accounts for 
4% to 5% of all new cancers. Approximately 30,000 
new cases of bladder cancer are found in the United 
States each year resulting in over 9,500 deaths. The 
incidence is three times more prominent in men than 
in women and four times more common in whites 
than in non-whites. Age distribution reveals a peak in 
patients 75-84 years of age, and 80% of these tumors 
occur after age 50. 
The known and suspected causes of bladder can-
cer are grouped into four categories: 1) Industrial 
chemicals; 2) metabolites of foodstuffs; 3) tobacco 
tar; and 4) chronic mechanical irritation and infec-
tion. 
All but 3% to 4% of bladder tumors originate in 
the transitional cell epithelium . Transitional cell car-
cinoma of the bladder occurs in approximately 90% 
of the patients, with squamous cell carcinoma ac-
counting for 6% to 7% and adenocarcinoma 1 % to 
2%. Transitional cell carcinomas may be very small 
and papillary in character but may be multiple, large 
and sessile tumors; the surface may be intact or ulcer-
ated, crusted, and bleeding. Squamous cell cancer, on 
the other hand, is usually flat, ulcerated, and some-
times necrotic; adenocarcinoma appears grossly as 
transitional or squamous and must be differentiated 
microscopically. 
Diagnosis 
Painless, gross hematuria is found in 75% to 85% 
of the patients presenting with carcinoma of the blad-
der. As the tumor enlarges, other symptoms such as 
frequency, urgency, dysuria, and decrease in caliber 
or force of the urinary stream may be present. These 
symptoms may be secondary to infection of the blad-
der or may be irritations caused by the tumor. As the 
tumor progresses, the suprapubic pain and a palpable 
mass may become prominent, these being associated 
with obstructive uropathy and uremia. 
The diagnosis is made at the time of cystoscopy 
when a tumor is seen and biopsies can be obtained. It 
is important that a rectal and bi-manual examination 
be done to assess the size of the mass. A palpable, 
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hard, indurated mass is usually a sign of an advanced 
tumor and a poor prognosis. 
Intravenous urography is an important step in 
the assessment of the patient with bladder cancer. 
The urogram will indicate the functional status of the 
kidneys and the possibilities of ureteral obstruction. 
By using triple-phase contrast studies of the bladder, 
one can ascertain fixation of the bladder wall and the 
possibility of invasion. If this is combined with pelvic 
arteriography in conjunction with perivesical and in-
travesical gas or with computerized axial tomogra-
phy, a better evaluation of the size of the tumor may 
be found. 
Grading and Staging 
All tumors can be graded histologically based on 
the degree of cellular anaplasia. Grade I or well-
differentiated tumor has a much better prognosis 
than a grade III or IV or poorly differentiated tumor. 
Staging in the United States has usually been by the 
A, B, C, D classification of Jewett and Strong, and 
Marshall. Recently the TNM (Tumor, Nodes, Metas-
tasis) classification of the International Union 
Against Cancer has been publicized in order to get 
physicians in the United States to switch to that 
classification of all tumors. In general, however, a 
stage 0 tumor is one that is localized only to the 
mucosa; stage A is limited to the submucosa, and 
stage B, indicates that the tumor has invaded the 
bladder muscle but is less than half-way through the 
bladder wall. Stage B2 tumors extend through the 
bladder muscle but do not invade the perivesical fat, 
and stage C indicates perivesical fat involvement or 
involvement of the capsule of another organ. Stage 
D, tumors are those that have spread to the regional 
pelvic lymph nodes or have invaded the pelvic wall or 
rectus muscle or both. Stage 0 2 tumors exist when 
the tumor has spread beyond these limitations and is 
outside the pelvis and the immediate bladder area. 
Metastases occur most often to the regional lymph 
nodes, lungs, liver, and bone. 
Treatment 
The treatment of the patient with a superficial 
tumor is usually by means of endoscopic surgery with 
transurethral resection. Careful follow-up examina-
tion with repeat cystoscopies every three months for 
one year, and every six months for five years, and 
every year thereafter are necessary in order that any 
residual or recurrent tumors may be promptly found 
and the appropriate treatment instituted. For the pa-
tient with multiple recurring tumors, the use of intra-
vesical therapy (ThioTepa), partial or total removal 
of the bladder, or radiation are possible therapeutic 
choices. For the patient with invasive transitional cell 
carcinoma, endoscopic procedures are not adequate. 
One cannot endoscopically tell the degree and extent 
of the tumor, therefore, an open surgical procedure 
with removal of the entire tumor or radiation therapy 
is indicated. It would appear as of this writing, that 
the best results are obtained from preoperative radia-
tion followed by open surgical extirpation of the tu-
mor, usually a radical cystectomy with urinary diver-
sion. There is some discussion about whether 2,000 
rads in one week , 4,000 rads in 4 weeks, or 4,500 rads 
in 6 weeks followed by either immediate or delayed 
cystectomy is best. 
Chemotherapy 
Long-term survival is rare once the tumor has 
spread beyond the confines of the bladder. One 
means of destroying metastases, however, may be 
through the use of combinations of chemotherapeutic 
agents. Drugs used in the management of patients 
with transitional cell carcinoma of the bladder have 
been 5-fluorourocil, bleyomycin, adriamycin, cyclo-
phosphamide (Cytoxan) and the cis-platinum com-
pounds. 
Testicular Carcinomas and Carcinoma of the 
Prostate 
PAUL F. SCHELLHAMMER, M.D. 
Associate Professor of Urology, Eastern Virginia Medical School, Norfolk, Virginia 
TESTICULAR CARCINOMAS 
Incidence 
Testicular neoplasms are relatively rare with ap-
proximately two new cases per 100,000 male popu-
lation occurring per year. The peak occurrence is 
between the ages of 20 .and 40. Because of their 
highly malignant characteristics testicular neoplasms 
must be treated aggressively if cure is to be achieved. 
Etiology 
The most significant etiologic factor is the pre-
disposition for the occurrence of carcinoma in the 
cryptorchid or undescended testicle. The cryptorchid 
testis is at 40 to 50 times the risk of the normal scrotal 
testicle for developing a cancer; various theories for 
this predisposition to malignancy have been pro-
posed. The most likely is that the cryptorchid testicle 
is inherently abnormal (a very strong argument also 
to explain its failure to descend) and therefore pro-
vides a fertile ground for neoplastic change. 
Histology 
Testicular tumors may be divided into neo-
plasms of germ cell origin (arising from the spermato-
gonia within the seminiferous tubules) and of non-
germ cell origin (arising from the supporting Leydig 
and Sertoli cells). The latter constitute only 5% of all 
testicular tumors. 
For purposes of histology and treatment regi-
mens the germ cell tumors are divided into the semi-
Correspondence and reprint requests to Dr. Paul F. Schell-
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nomatous tumors which are most common, con-
stituting approximately 60% of all testicular tumors, 
and the non-seminomatous tumors constituting the 
remaining 35% of tumors. The non-seminomatous 
tumors consist of embryonal carcinoma, teratocarci-
noma, teratoma, or choriocarcinoma. Rarely do each 
of these types exist in absolutely pure form; most 
nonseminomatous tumors combine the elements of 
embryonal and teratomatous carcinomas and these 
may have elements of choriocarcinoma as well. With 
the exception of pure choriocarcinoma, a distinctly 
rare entity comprising less than 1 % of tumors, the 
treatment regimen for the nonseminomatous tumors 
is identical to and independent of the percentage of 
each histologic type that constitutes the mixed tumor. 
Diagnosis: 
All testicular masses must arouse suspicion of 
carcinoma and some swellings such as testicular he-
matomas, orchitis, and epididymitis may cause in-
duration difficult to distinguish from a tumor diag-
nosed only by inguinal exploration and biopsy. 
Treatment 
When a testicular mass is suspect of carcinoma, 
it must be explored through an inguinal incision. A 
rubbershod or umbilical tape is used to obstruct the 
venous return and therefore reduce or eliminate em-
bolic dissemination during manipulation of the tes-
ticle. If there is some doubt about the diagnosis, the 
testicle is isolated with towels, and a biopsy and a 
frozen section are performed prior to orchiectomy 
and removal of the cord. The testicle must never be 
biopsied through the scrotum, either by incision or by 
needle aspiration; by doing so an entirely new nodal 
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chain for metastases is established. The testicle drains 
to the para-aortic nodes, the scrotum to the inguinal 
nodes. If the tumor cells seed in the scrotal incision, 
which can easily occur, then the entire inguinal chain 
is at risk for embolic metastases. 
The diagnosis of testes tumors is too often de-
layed for a number of reasons. Routine and careful 
bi manual examination of the testes is often omitted in 
routine examinations. Furthermore, patients who 
note testicular masses are often reticent to present 
their complaints to a physician because of embarrass-
ment, or fear of association with venereal disease. 
Metastatic evaluation. Once a diagnosis is made 
a number of radiologic studies, serum studies, and 
urine studies are warranted to stage the neoplasm and 
identify areas of metastases. The chest represents a 
common area of distant metastases and should be 
evaluated not only by anteroposterior and lateral x-
ray, but by pulmonary tomograms. Lesions are fre-
quently bilateral and multiple. The primary route of 
drainage of the testicular lymphatics is to the para-
aortic and paracaval nodes between the superior mes-
enteric and the inferior mesenteric arteries. Cross-
over drainage does occur and is most frequent from 
the right side to the left. Bipedal lymphangiography is 
of importance in identifying spread to the retro-
peritoneal nodes . Para-aortic and paracaval nodes 
are well visualized as is, frequently, the supraclavicu-
lar node. Intravenous pyelogram also assesses the 
retroperitoneum by evaluation of renal and/ or 
ureteral deviation, compression, and deformity. 
Computerized axial tomography (CT) scanning and 
ultrasound studies can be used to delineate retro-
peritoneal masses precisely and may be used as 
noninvasive techniques to follow these masses peri-
odically during the course of chemotherapy or radio-
therapy to evaluate treatment. 
Staging of testes tumors is as follows: 
Stage A: Tumor limited to testes, that is, no me-
tastases. 
Stage B: Tumor present in testes with metastases 
limited to regional nodes, that is, para-
aortic nodes below diaphragm. 
Stage C: Tumor present in testes with metastases 
beyond regional nodes, that is, metas-
tases to scalene node, lung, bone, liver, 
and so forth . 
Seminomatous tumors. These neoplasms are 
characteristically very radiosensitive. Radiotherapy 
constitutes the main method of treatment and rarely, 
if ever, is surgery indicated. If the tumor is Stage A 
(negative lymphangiogram and pulmonary tomo-
grams ), radiation is given in the dose of 2,500 R to 
the ipsilateral-iliac nodes and to the para-aortic 
nodes bilaterally to the level of the diaphragm. 
If the tumor is Stage B (evidence of nodal in-
volvement on lymphangiogram), the fields are ex-
tended so as to include the mediastinum and bqth 
supraclavicular areas, and the infradiaphragmatic 
area is treated to 3,000 R. The 5-year survival rate for 
patients with Stage A tumors, so treated, ranges 
around 95%. If the tumor is Stage B (evidence of 
positive para-aortic nodes), the 5-year survival rate 
will range around 80%. 
If the tumor is Stage C (evidence of pulmonary 
visceral or osseous metastases), radiation therapy 
may be given to these areas of metastatic involvement 
if they are relatively isolated, that is, one or two 
pulmonary nodules in one lung lobe. If disease is 
more diffuse, however, a radiomimetic chemothera-
peutic agent, either chlorambucil (Leukeran) or cy-
clophosphamide (Cytoxan) is used . Five-year sur-
vival rates for Stage C tumors range between 40% and 
50%. 
The only indication for surgery for semi-
nomatous tumors arises with the failure of what has 
been diagnosed as seminoma to respond satisfactorily 
to radiotherapy. In such a case one must suspect the 
presence of non-seminomatous elements, and surgery 
with excisional biopsy will eliminate the lesion, con-
firm a change in histology, and dictate a change in 
treatment to that used for non-seminomatous neo-
plasms. 
Non-seminomatous tumors. There is significant 
controversy as to the optimal management of non-
seminomatous tumors with North American urologic 
centers applying surgery, and European centers em-
ploying radiation therapy as the primary modes of 
treatment of the retroperitoneal area . Non-semi-
nomatous tumors are much more difficult to con-
trol with radiation than the seminoma and there-
fore radiation failures are more common . 
In the United States a non-seminomatous neo-
plasm is approached as follows: if the tumor is Stage 
A, a retroperitoneal node dissection is undertaken; if 
lymph node dissection reveals no evidence of histo-
logic metastases to the nodes, no further treatment is 
undertaken; and if the nodes are positive, chemo-
therapy is administered as the tumor is pathologi-
cally Stage B. 
If the tumor is Stage B, a node dissection is again 
performed and chemotherapy instituted postopera-
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tively. If nodal dissection is incomplete or there is 
tumor spillage, radiotherapy postoperatively to the 
retroperitoneal area is recommended. Chemotherapy 
is administered for two years after the last evidence of 
clinical disease is noted. 
If the tumor is Stage C, chemotherapy is insti-
tuted and if clinically measurable metastatic disease 
regresses, a node dissection is then considered. 
Five-year survival rates for Stage A, non-semi-
nomatous tumors range from 85% to 90% (the pa-
thologist is not always 100% accurate and may have 
missed microfoci in the excised lymph nodes and/ or 
metastases may have skipped the retroperitoneal 
nodes and dissiminated distantly without nodal in-
volvement). Five-year survival rates for Stage B dis-
ease are 60% to 70% and for Stage C , 25% to 30%. 
Tumor markers. Until recently, 24-hour urinary 
choriogonadotropin was measured in patients with 
testicular tumor in an effort to identify those with 
choriocarcinoma which as a functioning cell would 
produce choriogonadotropins detectable in the urine. 
The assay used is a biological one and has all the 
inherent difficulties of bioassays. 
A serum radioimmunoassay has been developed 
to overcome this difficulty. It measures the B chain of 
human choriogonadotropin (termed Beta sub unit) 
and is very sensitive and specific. Any elevation in the 
male is abnormal and indicates the presence of func-
tioning tumor cells. 
Alpha-fetoprotein is a protein produced by the 
fetus, but its production ceases and levels fall to 
nanogram marks soon after birth. Testis carcinoma 
cells may revert to the metabolic machinery of the 
fetal cell and produce alpha-fetoprotein , causing in-
creased serum levels. Like the Beta sub unit, elevated 
alpha-fetoprotein identifies the presence of active tu-
mor. 
Tumor markers are sensitive indicators of resid-
ual microfoci of disease long before any evidence of 
clinical or radiologic disease may appear. Active che-
motherapy must continue until tumor markers are 
reduced to and remain within normal levels . 
CARCINOMA OF THE PROSTATE 
Incidence 
The incidence of carcinoma of the prostate is 
steadily increasing; at the present time it is the most 
common genitourinary malignancy and the second 
leading cause of death from cancer among males 
in the United States. Its incidence of 60 new cases/ 
100,000 population and 20 deaths/ 100,000 popula-
tion per annum is exceeded only by carcinoma of 
the lung. The incidence of carcinoma of the pros-
tate increases with age, and autopsy studies have 
revealed it in 50% to 80% of males who have survived 
to age 80. Thus, we can a nticipate that with greater 
longevity the diagnosis of prostatic carcinoma will 
be made more frequently and the problems of 
treatment of a malignancy in an aged population 
will be of increasing concern . 
Etiology 
No specific carcinogen has been identified as the 
cause of prostate cancer. The most likely inciting 
event at present is a change in the hormonal milieu 
which occurs as a natural consequence of aging. The 
nature of the change and the hormone fluctuations 
involved are as yet unidentified. 
Anatomy and Histology 
The prostatic glandular elements can be divided 
into two major sectors-the inner periurethral glands 
and the peripheral tuboalveolar glands which are 
connected by long ducts to the prostatic urethra. The 
periurethral glands are those which most frequently 
give rise to benign hypertrophy and the peripheral 
tuboalveola r glands to adenocarcinoma of the pros-
tate. 
Natural History 
Carcinoma of the prostate is a neoplasm with 
varied growth characteristics and degrees of malig-
nancy. The tumor may be rapidly metastatic and 
cause death within one to two years or it may be 
slowly growing, metastasizing only five to ten, or 
even fifteen , years after discovery of the primary le-
sion; another five or more years may pass before the 
metastases become life-threatening. This variability 
makes it difficult to assess the efficacy of therapy, and 
makes it necessa ry to follow patients for ten to fifteen 
years after initiating treatment in order to judge its 
value. The reason for this is that, given a tumor with 
a relatively slow-growing and benign course, one can-
not state whether prolonged survival is based on the 
treatment administered or the low biologic potential 
of that tumor. Unfortuna tely, a t the present time 
there are few characteristics, other than the grade of 
anaplasia, that can be measured to identify at the 
time of diagnosis which tumors will follow a benign 
course from those which will not. 
86 SCHELLHAMMER: TESTICULAR AND PROSTATIC CARCINOMA 
Diagnosis 
While a high index of suspicion may be gener-
ated by induration felt on digital rectal examination, 
carcinoma of the prostate must be ultimately diag-
nosed by histologic proof of malignancy. A number 
of other causes for induration of the prostate include 
prostatic calculi, granulomatous prostatitis, nodular 
prostatic hypertrophy and, more rarely, tuberculous 
granulomas. Once a suspicious area of in duration or 
nodularity is identified a transperineal or transrectal 
needle biopsy employing the Vim-Silverman needle is 
used to obtain tissue for histologic examination. 
Other warning signals in the elderly male of 
prostatic cancer include the onset or recent ex-
acerbation of low back pain, possibly a reflection of 
osseous metastases; the presence of sciatic pain, pos-
sibly a reflection of sciatic nerve impingement by 
massive retroperitoneal lymphadenopathy secondary 
to metastases; and the rapid progression of bladder 
outlet obstruction which can be identical to that seen 
with benign prostatic hypertrophy (BPH). 
Radiographic identification of carcinoma of the 
prostate is facilitated by the characteristic radiodense 
or osteoblastic lesions most frequently found in the 
pelvic bones and the lumbosacral spine. These may 
be identified on routine skeletal survey, but more 
early identification is provided by the technetium 99 
phosphorous bone scan which identifies metastases 
prior to radiographic skeletal changes. (It has been 
shown that more than 50% of the bone must be 
destroyed or replaced by malignancy before a routine 
skeletal survey becomes positive). Intravenous pyelo-
graphy may demonstrate obstruction at the ure-
terovesical junction secondary to prostatic malignant 
growth and, specifically, involvement of the seminal 
vesicles. Also the ureters may be displaced by retro-
peritoneal metastatic adenopathy. 
Biochemical or serum abnormalities occur with 
prostatic carcinoma. Serum acid phosphatase repre-
sents· the most characteristic and distinct abnormal-
ity; in essence, it is a tumor marker. It can frequently 
be used to identify the presence of metastatic disease, 
and its levels may be followed as a means of mon-
itoring treatment; however, it is not a specific test as 
acid phosphatase may be elevated in a number of 
other diseases such as pulmonary embolism, muscle 
necrosis, Gaucher disease, and osteosarcoma, to 
mention a few. It is also not a very sensitive marker as 
diffuse metastases may be present in the face of a 
normal acid phosphatase. The recent development of 
a radioimmunoassay for measurement of prostatic 
acid phosphatase offers significant advantages for tu-
mor staging, and follow-up. The immune assay is 
specific for the prostatic fraction of acid phosphatase 
and is sensitive to extremely minor changes in serum 
levels of the enzyme. Elevation of alkaline phospha-
tase is a reflection of bony destruction and repair. 
Serum calcium may be elevated as a result of. exten-
sive osseous metastases. 
Treatment 
Many methods of treatment are used either indi-
vidually or in combination. Transurethral resection 
of the prostate is used to relieve obstruction. This is 
obviously palliative and relieves symptoms but does 
nothing to stem or alter the growth of the neoplasm. 
Radical prostatectomy, namely the total removal of 
the prostate gland and the seminal vesicles, is per-
formed with the intent to cure by removal of all 
neoplasm. Curative radiation therapy delivered from 
a linear accelerator or cobalt source is directed at the 
prostate and often the pelvic lymph nodes as well. 
Interstitial implantation of radioactive seeds is used 
in an effort to deliver high local doses. 
Treatment is based on the staging of the disease 
at the time of presentation: Stage A-carcinoma en-
tirely unsuspected on physical examination, or on 
serum chemical or radiographic examination but 
which is found incidentally on pathologic examina-
tion of the prostate excised for presumed BPH, that 
is, in the transurethrally resected prostatic chips or 
the prostate enucleated by an open technique. Stage 
B-tumor confined to the prostate gland on physical 
examination specifically without lateral or seminal 
vesicle extension; Stage C-tumor locally confined to 
the pelvis but demonstrating lateral extension and 
seminal vesicle invasion; Stage D-metastases to 
lymph nodes, bone, lung, and so forth. 
Management of Stage A depends to a large ex-
tent on the patient's age, the grade of lesion, and the 
extent of the involvement. When only microfoci of 
well differentiated neoplasm are present, it is reason-
able to pursue no further treatment. If the tumor is 
more extensive or poorly differentiated, treatment is 
as outlined for Stage B. 
For Stage B, either radical excision of the pros-
tate and seminal vesicles (radical prostatectomy) or 
treatment with external beam radiotherapy or inter-
stitial implantation of radioactive sources (1-125 
seeds) may be employed. The advantages of radio-
therapy are the inclusion of the periprostatic tissue 
(and thereby hoped-for sterilization of microscopic 
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extensions outside the prostate) and avoidance of the 
side effects of surgery, namely universal impotence 
and a 10% to 20% incidence of incontinence. 
The survival rates for Stage 8 carcinoma of the 
prostate are approximately 75% at five years, 45% to 
50% at ten years, and 25% to 35% at fifteen years. 
In Stage C carcinoma of the prostate, extension 
beyond the confines of the prostate and seminal vesi-
cles usually makes cure by radical prostatectomy 
highly unlikely; therefore, radiation therapy , either 
external beam or interstitial seeds, constitutes the 
mainstay of treatment. Occasionally it is also neces-
sary to relieve prostatic obstruction by transurethral 
prostatectomy either before treatment or immedi-
ately afterwards. Five- and ten-year survival rates for 
Stage Care approximately 45% and 30% respectively. 
The philosophy for treatment of Stage D carci-
noma of the prostate varies throughout the country . 
It is our policy to await the appearance of symptoms 
prior to the institution of therapy. Cure of Stage D 
prostatic neoplasm has not been documented, and 
therefore palliation of symptoms, and prolongation 
of survival remain the primary objectives of treat-
ment. Conditions warranting treatment include sys-
temic symptoms such as weight loss, fatigue, weak-
ness , bone pain, ureteral obstruction, and bone 
marrow replacement as evidenced by anemia. 
Hormonal manipulation (estrogen or or-
chiectomy) is the mainstay of treatment for meta-
static carcinoma of the prostate . Dramatic relief from 
pain and regression of metastases, and at times com-
plete disappearance of the primary prostatic lesion, 
follow the administration of hormones, or castration. 
The administration of estrogens works via the nega-
tive feedback system whereby high-estrogen doses 
suppress luteinizing hormone (LH) and follicle-stim-
ulating hormone (FSH), both of which are pituitary 
trophic hormones stimulating the testes to produce 
testosterone . Orchiectomy removes the source of 
androgen production. It is felt at the present time that 
either one of these modes is equally effective and can 
be expected to produce regression in approximately 
80% of patients with prostate carcinoma. There is no 
documented advantage from using both methods, 
that is, estrogen plus orchiectomy as opposed to ei-
ther one or the other alone, nor unfortunately is a 
second regression seen with any frequency by apply-
ing one of these modes when a relapse occurs after 
the institution of the other. 
Estrogens have certain distinct disadvantages; an 
orally ingested pill is required daily , nausea can oc-
cur, as can gynecomastia and other secondary sex 
changes . Of greater significance is data demonstrat-
ing an increased incidence of death from cardiovascu-
lar disease, na mely fluid retention, pulmonary edema, 
and congestive heart failure in patients receiving es-
trogen therapy. Orchiectomy, a simple surgical pro-
cedure that can be performed under local anesthesia , 
avoids these secondary effects of estrogen treatment. 
Other forms of hormonal ablation include adre-
nalectomy and hypophysectomy, but these are rarely 
used and have not been consistently successful in 
offering extended palliation. 
Local radiation therapy to painful osseous le-
sions may significantly relieve discomfort. Radiation 
is reserved for treatment of well-localized areas of 
painful metastases. 
Cytotoxic agents have just come under investiga-
tion in clinical trials and hold some promise for treat-
ment of estrogen failures . Investigation of certain 
cytotoxic agents linked to hormones (Estracyst = 
estrogen + nitrogen mustard; Leo = prednisone + 
chlorambucil) suggests that cytotoxic agents may be 
delivered within the prostatic cancer cell by steroid 
carriers which attach to hormone receptors . Other 
agents which depend on the acid phosphatase enzyme 
for cleavage to the active form are also in develop-
mental stages . 
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Adenocarcinoma of the Prostate: The 
Rationale and Role for Radiotherapy in its 
Management 
TAPAN A. HAZRA, M.D. 
Department of Radiology, Division of Radiation Therapy and Oncology, Medical College of Virginia, Health 
Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Until recently the treatment of carcinoma of the 
prostate was limited either to radical prostatectomy 
by the perinea! or retropubic route, or to hormonal 
manipulation. Approximately 5% of all patients with 
this disease are suitable candidates for radical sur-
gery. Hormonal manipulation is palliative in nature 
and is generally used when there is evidence of meta-
static disease (in about 50% of patients). There thus 
remains a group of patients (40% to 45%) in whom 
the disease is localized, yet too extensive for surgical 
treatment, for whom definitive radiotherapy can play 
a major role. 
Pre-treatment Evaluation 
Once the histological diagnosis of carcinoma of 
the prostate has been made it is desirable to delineate 
the exact extent of disease in order to provide certain 
guidelines for optimal management and for predict-
ing prognosis. In an attempt to evaluate the various 
diagnostic procedures, we at the Medical College of 
Virginia are conducting an ongoing study where all 
patients with clinically localized prostatic carcinoma 
undergo the following work-up: 
1. Laboratory Studies 
a) WBC, hematocrit, platelets 
b) Total and prostatic fraction of acid phos-
phatase (blood is obtained either prior to 
or at least 24 hours after rectal examina-
tion). 
Correspondence and reprint requests to Dr. Tapan A. Hazra, 
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c) Alkaline phosphatase and BUN. 
d) Bone marrow biopsy for histological ex-
amination, and radioimmunoassay for 
prostatic acid phosphatase. 
2. Radiological Studies 
a) Chest x-ray 
b) Intravenous pyelography 
c) Bipedal lymphangiogram 
d) 99m Tc Labeled di-phosphate bone scan 
Radiation Therapy 
Although the use of ionizing radiation in the 
treatment of carcinoma of the prostate was first re-
ported in 1911 by Pasteau, 1 the majority of reports 
have appeared within the last ten years. In a recent 
comprehensive review of the subject Ray and his 
colleagues 2 have documented clinical studies which 
collectively report on 880 cases in which external 
beam irradiation was the primary mode of treatment. 
They have concluded "that potentially tumoricidal 
dosage of irradiation can be delivered to the prostate 
with relative safety and in general the initial response 
of the local tumor to irradiation in survival rates at 
five years were encouraging." 
Results 
Local. In general , the reports of various authors 
support our experience that 70% to 80% of patients 
show marked resolution of the disease within six 
months on clinical examination. We do not, at the 
present, recommend post-treatment prostatic 
biopsies as a routine procedure. 
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Survival. On reviewing the results of various in-
vestigators dealing with the definitive treatment of 
adenocarcinoma of the prostate with megavoltage 
irradiation therapy, one finds that the five-year sur-
vival rate varies from 60% to 70% and the ten-year 
survival rate varies from 30% to 40%. Ray and his 
colleaguess from Stanford University have reported 
the results of treatment for two clinical groups of 
patients based upon the extent of the disease as deter-
mined by digital examination . In one group of pa-
tients the disease was limited to the prostate and this 
group of patients had a 71 % and 41 % survival rate at 
five and ten years respectively. In the other group of 
patients the disease had extracapsular extension and 
this group of patients had 41 % and 31 % survival rates 
at five and ten years respectively. Hillaris and his 
colleagues4 from Memorial Hospital have reported 
that all patients with intracapsular diseaself i. T2 , 
and Ts) and negative lymph nodes were alive and free 
of disease at five years while disease-free survival 
decreased to 70% in patients with extracapsular dis-
ease and negative nodes or in patients with intra-
capsular disease with positive nodes. Only 50% of 
patients with extensive local disease (Ts and T4 ) and 
positive nodes were alive without evidence of disease 
at five years. It has been my experience that dissemi-
nation of disease is more frequent in patients with a 
large primary tumor, with a high-grade tumor , and in 
the presence of histologically positive lymph nodes. 
In addition, there is rapid systemic dissemination of 
the disease once the para-aortic lymph nodes are 
involved. 
Present Area of Clinical Investigation 
The major cause of failure of definitive radio-
therapy in carcinoma of the prostate is the spread of 
tumor, outside the high dose of radiation field, either 
to the lymph nodes or to the bones. It is generally 
accepted that young patients (below 65 years), pa-
tients with a high-grade tumor and with diffuse in-
volvement of the prostate gland (multiple chips in-
volved, post-transurethral resection of the prostate) 
have a poor survival rate even when they present with 
early (stage A) disease. It remains to be seen whether 
definitive radiation therapy in this select group of 
patients with stage A carcinoma of the prostate will 
alter the natural history and provide an improved 
survival rate. 
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Management of Acute Glomerulonephritis 
DONALD OKEN, M.D. 
Professor and Chairman, Division of Nephrology, Medical College of Virginia, Health Sciences Division of 
Virginia Commonwealth University, Richmond, Virginia 
Glomerulonephritis is responsible for over one 
half of all cases of end-stage chronic renal failure 
and, in its most fulminant form, is a cause of acute, 
irreversible renal failure. Electron microscopy and 
immunofiuorescent studies together with newly rec-
ognized clinical associations have revealed a wide 
variety of histologic subgroups and myriad etiologies 
for what was once regarded as a single, simple entity. 
The addition of electron microscopy has lent an en-
tirely new dimension to the delineation of glomerulo-
nephritis subtypes and offers a more reasonable ap-
proach to the search for treatment of these subtypes. 
It is, after all, not unreasonable to suppose that dif-
ferent etiologic factors and host responses are in-
volved in the various pathologic lesions so clearly 
defined on electron microscopy. Immunofiuorescent 
studies identify the presence of immune globulins and 
complement components in glomerular lesions and 
aid in recognition of their localization sites; they may 
reveal the contribution of fibrin deposition or specific 
antigens in the pathogenesis of glomerular in-
volvement. 
Most, if not all, forms of glomerulonephritis are 
acknowledged to be the result of immunologic proc-
esses, and many can be mimicked by immunologic 
manipulations in laboratory animals. A growing 
body of research data . has incriminated circulating 
immune complexes, activation of the complement 
cascade and the coagulation system, antibodies di-
rected specifically against the glomerular basement 
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membrane, proteolytic activity of leukocytes, and 
other phenomena in the mediation of particular types 
of glomerular injury. In experimental animals, at 
least, manipulation of the antigen: antibody ratio or 
depletion of complement and/ or polynuclear leuko-
cytes may blunt the severity of, or prevent entirely, 
lesions which are otherwise inevitable and severe. In 
the rabbit, the prophylactic administration of anti-
coagulants has marked beneficial effects on the devel-
opment of glomerulopathy. Unfortunately, com-
parable benefit is not observed when these maneuvers 
are performed after glomerular abnormalities are al-
ready established. 
Most experimentally induced glomerulopathies 
are self-limiting and of brief duration. Aside from the 
maneuvers mentioned in the previous paragraph, 
therapy which would be considered suitable for use in 
man appears for the most part to be of little benefit in 
the laboratory. In man, the value of currently avail-
able treatments intended to halt or reverse the pro-
gression of glomerular abnormalities is no more im-
pressive. Corticosteroids, immunosuppressive agents, 
and anticoagulants are of proven value in only a 
minority of histologically specific lesions (for ex-
ample, hypersensitivity angiitis, Wegener gran-
ulomatosis, minimal lesion nephrotic syndrome), and 
their efficacy in other forms of glomerulonephritis is 
strongly debated. The very existence of such debate, 
over 25 years after the introduction of steroid therapy 
and 15 years after azathioprine (Imuran) became 
available, should indicate that current treatment 
modes are less than optimally effective. New forms of 
treatment must be developed. 
Working on the assumption that immunologic 
mechanisms are the key to the appearance of glo-
merular injury, one would ideally search for new 
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means of turning off or minimizing the impact of 
those mechanisms, an approach which meets with 
considerable success in the prevention of renal trans-
plant rejection. Having been largely unsuccessful in 
achieving suitable manipulation of immune mecha-
nisms with our present knowledge, we can at least 
attempt to minimize the impact of the immune sys-
tem on the kidney. In that regard, a new approach to 
the problem is under study here at the Medical Col-
lege of Virginia and elsewhere-plasmapheresis. This 
technique involves the removal of the patient's 
plasma and replacing it with donor's plasma so as to 
remove circulating immune complexes and/or pre-
formed antikidney antibodies. Preliminary data in-
dicate that, in selected cases, significant improvement 
in renal function may follow such treatment. The 
overall value of plasmapheresis is still under review, 
however, and will not be known until suitable num-
bers of patients have received this treatment. 
Use of the "Melbourne cocktail"-a combina-
tion of dipyridamole, corticosteroid and heparin 
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therapy-has been reported to reverse the most ful-
minating and devastating form of acute glomerular 
disease termed "rapidly progressive glomerulone-
phritis." While the clinical presentation of oligoa-
nuria with virtually complete cessation of glomerular 
filtration in children is often completely reversible, it 
is rarely so in adults. Fibrin deposition, formation of 
luxuriant epithelial crescents, and marked cellular 
proliferation of the glomerular tuft typify this sub-
group of patients. Employing a treatment which af-
fects platelet aggregation and intracapillary coagu-
lation seems entirely rational but is not without 
hazard to the patient. Once this particular form of 
fulminating glomerulonephritis is recognized, how-
ever, the prognosis for return of renal function is so 
poor that the cocktail is being investigated in several 
centers. Evaluation of such treatment requires experi-
ence, ideal patient management and careful patient 
selection, and should be undertaken only under the 
most stringent precautions if we a re to establish its 
efficacy in a controlled fashion. 
The Management of End-Stage Renal Disease 
(ESRD) 
WILLIAM F. FALLS, JR., M.D. 
Medical Service, Veterans Administration Hospital, and Department of Medicine, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
End-stage renal disease (ESRD) may be defined 
as a state of renal insufficiency of such severity that 
the affected individual is unable to carry out his usual 
activities because of symptoms usually attributed to 
the uremic syndrome. This state has been reached, or 
is imminent, when the serum creatinine concentration 
rises above 10 mg/ 100 ml and/or the creatinine clear-
ance falls below 5 to 10 ml/min and reversible causes 
of renal failure such as obstructive uropathy, bilateral 
renal vascular disease, severe accelerated hyper-
tension, hypercalcemic nephropathy, uric acid ne-
phropathy, and certain immunologic diseases such as 
Wegener granulomatosis have been excluded. Pro-
spective analysis of a population of patients meeting 
these biochemical criteria has clearly shown that at 
least 80% will require dialysis within 150 days and 
40% will require this method of treatment within 60 
days to sustain life. 1 Thus, when ESRD is reached, 
weighty decisions concerning the patient's care must 
be made. It is the purpose of this paper to review the 
management of ESRD and to point out some of the 
problems which may complicate the several therapeu-
tic modalities. 
The alternative methods of management of the 
patient with ESRD are dialysis and transplantation. 
These two therapeutic modalities are by no means 
mutually exclusive and, as we shall see, should be 
considered complementary. However, virtually all 
patients must undergo a period of dialysis, even those 
awaiting transplantation. Therefore, dialysis is the 
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first mode of treatment encountered by a patient 
entering an ESRD program. 
At the present time there are few absolute con-
traindications to entrance into an ESRD program for 
dialysis and transplantation. However, patients with 
uncontrolled psychotic behavior, extreme old age, 
advanced artherosclerotic vascular disease, or dis-
seminated malignancy are probably not candidates 
for therapy. 
Principles of good conservative management of 
renal failure such as restriction of dietary protein, 
careful attention to fluid and electrolyte balance with 
tailoring of dietary sodium intake to the obligatory 
sodium loss, and the administration of sodium bi-
carbonate supplements and oral phosphate binders 
where appropriate may postpone the absolute need 
for dialysis or transplantation if introduced when the 
patient has moderately severe renal insufficiency. Re-
cent studies have demonstrated that the period of 
conservative management can be prolonged even fur-
ther by the administration of a special mixture of the 
keto-analogues of the essential amino acids.2 This 
maneuver allows for the dietary administration of 
very limited quantities of nitrogen and is predicated 
on the assumption that some of the urea nitrogen will 
be recycled into the synthesis of essential as well as 
nonessential amino acids. Unfortunately, these keto-
acids are not commercially available at present, but 
perhaps will be in the future. 
Survival rates for patients treated by hemo-
dialysis at home and those who have received a well-
matched transplant from a living related donor are 
both greater than 80% at two years.3 It is worth 
noting, however, that this represents patient survival 
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and not graft survival which is only about 70%, thus 
indicating that some 10% to 15% of the transplant 
recipients who survive two years have suffered an 
undetermined amount of morbidity in association 
with rejection of their graft . Survival with in-center 
dialysis and cadaver transplantation is less good, with 
a two-year survival rate of approximately 70% in each 
case.3 The two-year graft survival in patients with 
cadaver transplants is less than 50%. These statistics 
suggest the desirability of home dialysis and living 
related donor transplantation, but do not demon-
strate a clear superiority of in-center dialysis or cada-
ver transplantation. Thus, factors other than survival 
must be considered in selecting a mode of therapy. 
Age is a major factor which may influence thera-
peutic selection. Children and adolescents tend to 
have diminished growth and maturation while on 
dialysis4 and they frequently rebel against the rigid 
dialysis schedule. Therefore, most authorities favor 
transplantation as a mode of therapy in the young.5 
On the other hand, older individuals with a well-
established, stable lifestyle may prefer not to run the 
risk of the lost time from work and the potential 
complications of transplantation. The patient's psy-
chological state also may be of importance in select-
ing a mode of therapy. Some older patients, like the 
children, may find the confining life of the dialysis 
patient to be more than they can tolerate and be 
willing to risk the uncertainties of cadaver trans-
plantation. 
The presence of complicating medical disorders 
may influence the type of management selected . Dia-
betics may fare better with transplantation because 
progression of atherosclerotic vascular disease and 
retinopathy may be less rapid than on dialysis. 5 Pa-
tients with certain enzyme defects such as Fabrey 
disease may also benefit from transplantation be-
cause the transplanted organ may serve as a source of 
the defective enzyme.6 On the other hand, trans-
plantation is contraindicated in patients with anti-
basement membrane antibody nephritis with circulat-
ing antibodies7 and in patients with large quantities 
of circulating cytotoxic antibodies7 because of the 
likelihood of rapid graft destruction after trans-
plantation. Additionally, the immunosuppressive 
medication given to patients may allow for enhanced 
tumor growth, and most surgeons will not consider 
performing transplantation in a patient with a history 
of malignancy unless there is clear evidence that the 
patient has been tumor-free for at least one year.7 The 
presence of lower urinary tract dysfunction and an 
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inadequate bladder are still considered relatively 
strong contraindications to transplantation. 
Having decided that a patient's life will be sus-
tained, a decision must be made about the form of 
dialysis to be instituted. Although chronic peritoneal 
dialysis has been an effective modality in some 
hands,8 most authorities consider it to be less desir-
able than chronic hemodialysis, and the remainder of 
this discussion will be concerned with hemodialysis. 
Two types of vascular access are available for 
connecting the patient to a dialysis machine. These 
are the silastic, external arteriovenous (AV) shunt9 
which protrudes through the skin and the internal 
AV fistula communication, using the patient's own 
vessels 10 or a foreign graft material. 11 The latter lies 
immediately under the skin and must be punctured 
with a needle at each dialysis. The fistula is preferred 
by most physicians and patients because of the free-
dom of movement and the safety which it provides. 
Where possible, it is our policy to anticipate the 
ultimate need for dialysis and to have the surgeon 
electively establish an AV fistula at about the time the 
serum creatinine reaches a concentration of8 mg/100 
ml. This allows time for maturation of the fistula 
prior to its initial use, and obviates the need for 
emergency surgery to establish vascular access in an 
ill patient. 
Hemodialysis is usually initiated in the medical 
center, but when the patient has an acceptable helper, 
every effort should be made to encourage the couple 
to learn home dialysis. The training program can be 
mastered by anyone of average intelligence and takes 
about two months to complete. As mentioned pre-
viously, patients on home dialysis have better sur-
vival statistics and are better rehabilitated. 12 
Whether dialysis is performed at home or in a 
center facility, there are a number of common com-
plications of which the physician should be aware. 
Bacterial infection of the shunt or fistula is a frequent 
problem that may lead to metastasization and re-
quires aggressive drainage and antibiotic treatment. 13 
Hepatitis B infection has been a frequent occurrence 
among dialysis patients. 14 It presents a particular 
problem in dialysis units because patients may be-
come carriers and transmit the virus to staff and other 
patients. Virtually all patients on dialysis have some 
degree of anemia.15 In the past, transfusion of poten-
tial transplant candidates was kept to a minimum 
because of possible sensitization to transplant anti-
gens. However, recent evidence suggests that frequent 
transfusions may actually enhance rather than inhibit 
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the frequency of organ acceptance. 16 Therefore, 
transfusions, particularly of saline-washed red cells, 
are now being given with less concern than in the 
past. Pericarditis continues to be a frequent and 
poorly understood complication in the dialysis pa-
tient and it does not always appear to be a manifesta-
tion of inadequate dialysis .17 Hypertension is seen 
frequently in the dialysis population ahd may be re-
lated either to expansion of the extracellular fluid 
volume or to the release of pressor substances from 
the residual damaged kidneys .18 In the latter circum-
stance, bilateral nephrectomy may produce a dra-
matic return of the blood pressure to normal. 19 Neu-
ropathy is frequently noted at the onset of dialysis 
but seldom progresses if dialysis is adequate.20 Impo-
tence is seen more frequently than not in male dialysis 
patients, and dialysis against a bath containing a high 
concentration of zinc has recently been proposed as 
effective therapy.21 As more patients are sustained 
alive for prolonged periods of time it is becoming 
clear that osteodystrophy22 and accelerated athero-
sclerosis21 are problems of great magnitude. Therapy 
of the former includes the use of oral phosphate 
binders to maintain the serum phosphorus concentra-
tion levels at normal , and a supplemental vitamin D 
preparation to enhance intestinal calcium absorption; 
there does not appear to be any effective therapy for 
the latter. 
Many of the problems mentioned above will be 
corrected by a functioning transplant. However, 
there are a number of problems which are unique to 
the transplant population. Most of the difficulties 
associated with early transplant rejection are man-
aged by the transplant team prior to discharge from 
the hospital after surgery, and these will not be con-
sidered here. Chronic rejection may occur late after 
transplantation, is characterized by a slow deteriora-
tion in function , and is generally unresponsive to 
therapy. Infection remains the major cause of mor-
bidity and mortality among transplant patients.23 Be-
cause of the constant need for immunosuppressive 
medication these patients have an increased suscepti-
bility to both common bacterial pathogens and to 
opportunistic viruses such as herpes hominis and 
cytomegalovirus; fungi such as cryptococcus and as-
pergillus; and protozoa such as pneumocystis and 
toxoplasmosis . Hypertension also is a frequent com-
plication of transplantation and may be difficult to 
control. A diabetic diathesis may be brought out by 
the administration of steroids as immunosuppressive 
agents.24 Osteoporosis may develop as a complication 
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of long-term steroid administration.24 The constant 
immunosuppression may also allow for the develop-
ment of tumor growth and there is a much higher 
incidence of malignancy in transplant patients than in 
a comparable, non-immunosuppressed population.24 
Gastrointestinal bleeding is a feared complication of 
transplantation that is frequently fatal. 24 Con-
sequently, many transplant surgeons perform pro-
phylactic gastric surgery in any potential candidate 
who has the slightest history of ulcer disease. 
It is our feeling that selection of a proper thera-
peutic modality in a patient with ESRD requires 
careful consideration of the medical, psychological, 
social, and economic aspects of the patieht's illness. 
His needs may change through the course of illness 
and, as a consequence, the ESRD prescription may 
require alteration. Thus, a patient might initially be 
managed with home dialysis, receive a living related 
donor transplant after a sibling decided to become a 
donor, and return to home dialysis after rejection 
occurred. 
The economic costs of ESRD treatment are stag-
gering. 25 At present there are more than 37,000 indi-
viduals receiving some type of ESRD therapy in the 
United States at an annual cost of $902 million. By 
1982 it is projected that the cost for 55,900 patients 
will be 2.3 billion . Most patients are eligible for finan-
cial coverage of the major portion of their dialysis or 
transplantation cost either via private insurance car-
rier, Medicare, or the Veterans Administration. At 
present the annual cost of in-center dialysis is approx-
imately $23,400 while that of home dialysis is 
$12,480. The initial cost of hospitalization for trans-
plant surgery is about $17,000. These estimates do 
not include the cost of hospitalization for various 
complications of either the dialysis or transplant 
state; and, as suggested earlier, these may be formi-
dable. 
In the future, dialysis equipment may be made 
more compact and a satisfactory portable dialyzer 
may Q_e developed. The use of sorbent materials may 
allow dialysis with small quantities of fluid, and high 
potency antithymocyte globulin may improve the 
early survival of cadaver grafts. Techniques also may 
be developed for the stimulation of blocking anti-
bodies in the recipient which will allow for improved 
graft survival with lower doses of immunosuppressive 
drugs. However, none of these innovations seem 
likely to dramatically change the management of 
ESRD in the near future. 
The management of ESRD has been briefly re-
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viewed; both dialysis and transplantation are useful 
modalities of therapy and are not mutually exclusive. 
Management in a giv'en patient should be designed to 
best meet his medical, psychological, social, and eco-
nomic needs. 
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Evaluation and Management 
J. WILLIAM McROBERTS, M .D. 
Division of Urology/ Department of Surgery, University of Kentucky School of Medicine, Lexington, Kentucky 
Introduction 
At a time when limiting family size has become 
of national interest, increasing numbers of married 
couples are moving in a different direction-to over-
come infertility and conceive children. Reasonably 
reliable statistics indicate that approximately 3 .5 mil-
lion couples, or nearly 15% of those of childrearing 
age, are subfertile. If one adds the cases of secondary 
infertility, in which a pregnancy or a miscarriage has 
already occurred in the marriage but is followed by 
years of difficulty conceiving another child, the mag-
nitude of the infertility problem is indeed impressive. 
At the personal level, involuntary childless couples 
may suffer doubts about their own sexuality and are 
often caught in intense emotional, family, and so-
cietal pressures emanating from their inability to con-
ceive. 
Furthermore, the incidence of infertility seems to 
be slowly increasing due to a number of factors in-
cluding the increased risk of prolonged anovulation 
following the use of birth control pills and to adnexal 
infections associated with the use of intrauterine de-
vices. Additionally, there is a definite trend by women 
to delay having children until later in life and thus to 
bypass the time of their optimal fertility potential 
between 22 and 26 years of age. 
Whether or not the true incidence of infertility is 
increasing, there is a definite and substantial increase 
in the demand for treatment. This reflects a growing 
awareness by childless couples that treatment for in-
fertility in many instances can be effective and that 
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the number of babies available for adoption have 
been sharply reduced by birth control, liberalized 
abortion laws, and an increasing tendency of unwed 
mothers to keep their babies. 
Until recently, most physicians were not particu-
larly enthusiastic about treating patient infertility. 
The reasons for this attitude centered around a gen-
eral pessimism about being able to help the patient, 
combined with the fact that the physicians' training 
ill-prepared them for evaluating and managing these 
patients with the result that male infertility has prob-
ably been the most misunderstood item since the IRS 
short form. Presently, a more optimistic view is war-
ranted as therapy is now effective in achieving preg-
nancy for about 45% of these couples. 
The objective of this article is to present the most 
recent information regarding the clinical aspects of 
male infertility and subfertility. The information will 
be practical and directed to understanding both the 
causes of male infertility and the various methods of 
evaluating and managing male patients with this 
problem. 
Definition of Male Infertility and Subfertility 
Based on semen analysis, a precise definition of 
male infertility and subfertility is difficult because the 
quality of semen that will achieve a pregnancy for one 
couple and not another will vary due to the relative 
fecundity of the female partner and the variable inter-
action of infertility co-factors. In other words, data 
suggest that there are degrees df fertility for both 
sexes, depending on the partner. 1 Nevertheless, given 
a female partner who is fertile by most standards, 
lower limits for semen quality have been established 
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under which a pregnancy is likely to occur.2 - 4 These 
minimal values are as follows: 
Total ejaculate volume: 1.5-5.0 ccs 
Sperm count: 20 m/ cc 
Sperm motility: 60% motile 
Sperm speed: 2+ (Scale 1-4) 
Sperm morphology: 60% normal forms 
These minimal values must be considered as part 
of the overall semenogram and may be adjusted if 
one index is of particularly high quality, for example, 
a patient with a 10 m/ cc sperm density may well be 
fertile if his sperm motility is excellent. 
History and Physical Examination 
Beyond obtaining a basic medical and marital 
history, the infertility history should be directed at 
uncovering the specific factors that are known to 
contribute to subfertility. These factors can be conve-
niently divided into four groups: childhood illnesses; 
adult illnesses; drugs; and environmental-occupa-
tional hazards. 
Specific childhood illnesses that can adversely 
effect fertility include cryptorchidism, mumps, sper-
matic cord torsion, direct trauma, and the timing of 
puberty as well as specific surgical procedures includ-
ing herniorrhaphy, orchiopexy, hypospadias repair, 
urethroplasty, and Y-V plasty of the bladder neck to 
relieve "obstruction." 
Adult illnesses that are similarly important in-
clude tuberculosis of the genital tract, mumps, or-
chitis, prostatitis, epididymitis, gonorrhea, diabetes, 
vaginitis in the female partner, and such surgical 
procedures as noted under childhood illnesses plus 
retroperitoneal surgery (lymphadenectomy, sympa-
thectomy, and so forth), vasectomy, and prostatic 
surgery. 
Drugs that are known to interrupt or alter sper-
matogenesis include the nitrofurantoins, amebicides, 
hormones (for example, testosterone, estrogens, cor-
ticosteriods ), as well as most of the anti-cancer 
chemotherapeutic drugs . 
The patient's occupation may have a bearing on 
his fertility status if he is under a great deal of stress 
or if the testicles are exposed to undue heat or radia-
tion. 
The physical examination should include a thor-
ough examination of the external genitalia and pros-
tate. Testicular size and consistency are particularly 
important; measurement is facilitated by the use of 
calipers. The normal adult testis measures approxi-
mately 4.6 cm in greatest diameter (range 3.6-5.5 cm) 
and 2.6 cm in width (range 2.1-3 .2 cm). Because the 
germinal epithelium comprises about 80% of the· nor-
mal testicular mass, atrophy of the seminiferous tu-
bules will be reflected in a smaller than normal tes-
ticle. On the other hand, normal testicular size does 
not assure normal semen quality. If the patient's 
body habitus appears abnormal, laboratory investi-
gation should be directed at determining any abnor-
mality of the hypothalmic-pituitary-gonadal axis. 
The Semen Analysis 
The semen analysis is without doubt the single 
most important step in the evaluation of male infer-
tility. It is to male infertility what cystoscopy is to 
bladder tumors, that is, it is the most critical item in 
the initial eva luation process and is important in 
therapy foll ow-up. 
The semen analysis, or semenogram, is a study 
of the characteristics of the spermatozoa that are 
clinically important in assessing fert ility. While non-
cellular components of the semen also contribute to 
fecundity, for clinical purposes the semenogram will 
reflect their influence on the spermatozoa! character-
istics that are decisive in determining fertility poten-
tial, and a separate biochemical analysis of these 
components is neither necessary nor practical. 
Because of its importance, a minimum of two 
and preferably three semen analyses should be ob-
tained. Additionally , multiple collections are neces-
sary because of physiological variations in the same 
patient and because of technical variations in analyz-
ing the specimen, for example, acceptable counting 
errors vary from 10% to 20% with the same specimen. 
Preferably, the semen specimen should be col-
lected by masturbation into a clean, wide-mouthed 
glass or plastic container. The container, such as a 
standard urine specimen bottle or ointment jar, 
should be supplied by the physician to avoid facti-
tious results secondary to the container's previous 
contents or cleaning agents. The specimen should be 
kept warm and delivered to the laboratory for analy-
sis within 60-90 minutes. The timing of specimen 
collection should reflect the couple's usual coital fre-
quency pattern, or if that is variable, an abstinence 
period of 2-4 days is recommended . Personal or reli-
gious beliefs may require the use of a silastic seminal 
fluid collecting device. It is critical that the specimen 
represents the entire ejaculate since there are signifi-
cant variations in the seminal values from one por-
tion to the other with regard to motility, sperm den-
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sity, and viscosity as compared with the total 
ejaculate. 
The specific techniques of analyzing the semen 
will not be discussed because they are beyond the 
space limitations of this presentation and, addition-
ally, are available in recent texts. 5 Five principal in-
dices should be reported on the semen analysis. Rep-
resentative values for fertile men are as follows: 
1. Total ejaculate volume: 2-5 ccs 
2 . Sperm count (density in millions/ cc): greater 
than 50 m / cc 
3. Sperm motility(% motile cells): 65% to 85% 
4 . Sperm speed (forward progression speed): 3-4 
(scale 0-4) 
5. Sperm morphology: 60% to 85% normal oval 
forms 
Additionally: The specimen is normally viscous 
a nd opalescent with a grayish-white color. There 
should be no hyperviscosity, pyospermia, or signifi-
cant sperm agglutination. 
Systematic Approach to Male Infertility 
A systematic approach to male infertility can be 
facilitated with the use of the following diagnostic 
flow sheet (modified after Lipshult z6 ): 
PHYSICAL 
HISTORY 1-----1 EXAMINATION 
SEMEN ANALYSIS 
X3 
ABNORMAL 
SEM EN 
ANALYSIS 
NORMAL 
I 
Evaluate couple 
ASPERMIA AND 
AZOOSPERMIA 
ALL 
PARAM ETE RS ABNORMAL 
PREDOMINANCE OF SINGLE ABNORMAL PARAMETER 
The flow sheet is based on the semen analysis 
and the identification of the three broad seminal cate-
gories of: 1) aspermia and azoospermia, 2) pre-
dominance of a single abnormal parameter, a nd 3) 
all parameters abnormal. 
Aspermia and Azoospermia 
Somewhat less than 5% of male infertility pa-
tients will present with either aspermia or azoo-
spermia. In the aspermic patient there is failure of 
any ejaculate to appear at the time of orgasm. On the 
other hand , the azoosperm ic patient experiences both 
ejaculation and orgasm, but the ejaculate contains no 
spermatogenic elements . 
The absence of ejaculation in aspermic patients 
is generally due to neurogenic causes7 and, less com-
monly, to retrograde ejaculation. The neurogenic 
causes include pituitary tumors, olfactogenital dys-
plasia (Kallman syndrome), and absent contraction 
of the seminal vesicles and vasa differentia following 
retroperitoneal lymph node dissection for the treat-
ment of testi cu lar tumors (and not due to retrograde 
ejaculations as previously thought) . 
The neurogenic causes can be successfully 
treated in most cases by specific replacement therapy. 
The common causes of retrograde ejaculation 
include those in which the anatomy of the internal 
sphincter is disrupted as in transuretheral resec-
tion (TUR) of the prostate or vesicle neck surgery, 
or where the nerve supply of the internal sphincter 
is distrupted as in spinal cord injury , surgical sym-
pathectomy, chemical sympathectomy [guanethidine 
(sulfate) (Jsmelin)), and diabetes visceral neuropathy. 
Apart from a history of a previous elective vasec-
tomy, the azoospermic patient's differential diagnosis 
rests bet ween obstruction or atresia of the epididymal 
or vasal ducts and testicular failure as seen in ger-
minal cell aplasia, marked spermatogenic arrest, 
chromosomal defects, severe peritubular fibrosis, a nd 
Klinefelter syndrome. 
The seminal specimens of all azoospermic pa-
ti ents should be tested for the presence or absence of 
fructose: this is quantitatively determined by adding 
the reducing reagent resorcinol to a small portion of 
the seminal specimen and bringing it to a boil. 5 If 
fructose is present, an orange color will appear within 
half a minute of boiling. The presence of fructose, a 
product of the seminal vesicles, effectively rules out 
congenital bilateral absence of the vasa as the pres-
ence of the seminal vesicles depends on the existence 
of the vasa which embryologically give rise to the 
former. On the other hand, the presence of fructo se 
only rules out bilateral obstruction of the ejaculatory 
ducts but does not assure ductal patency throughout 
the vasa and epididymi . Therefore, in a setting of 
azoospermia and a normal testicular biopsy, vaso-
grams should be obtained to identify the site of ob-
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struction which can be corrected surgically by micro-
surgical techniques, depending on its location. 
Predominence of a Single Abnormal Parameter 
Approximately a third of subfertile male patients 
will have a semen analysis characterized by the pre-
dominence of a single abnormal parameter, most 
commonly sperm viability/motility. Asthenospermia, 
a decrease in sperm motility below 60%, can be 
caused by a number of factors including sperm im-
mobilizing antibodies, infection, endocrinopathy, 
varicocele, and epididymal dysfunction. 
It is now widely appreciated that testicular 
spermatozoa acquire their fertilizing capacity and 
motility as they pass through the epididymis. Impor-
tant for these considerations is the fact that testoste-
rone is transported, bound to androgen-binding-pro-
tein, from the seminiferous tubular fluid to the 
epididymis in concentrations about 20 times that of 
serum. In the epididymis, the antigen-binding-protein 
disappears and the free testosterone diffuses into the 
epididymal cell. Therefore, the functional integrity of 
the epididymis may be compromised either by failure 
of the Leydig cells to produce high enough local 
concentrations of testosterone, by failure of the Ser-
toli cells to produce adequate amounts of androgen-
binding-protein, or by failure of the epididymal epi-
thelium to utilize effectively the free testosterone. In 
any event, the end result is a local epididymal envi-
ronment not optimal for the normal development of 
sperm motility. Therapy is directed at improving the 
local epididymal environment by the administration 
of gonadotropins which stimulate Leydig cell produc-
tion of testosterone and androgen-binding-protein by 
the Sertoli cells. Therapy has been effective in some-
what less than half the patients so treated. Low-dose 
androgen therapy in the form of fluoxymesterone 
(Halotestin) 2-5 mg, b.i.d., has not been effective. 
Additionally, epididymal dysfunction may be 
secondary to complete or partial obstruction, or to 
changes in the functional integrity of the epididymis 
itself due to such conditions as epididymitis. Treat-
ment is directed at the specific disorder and involves 
short-circuiting the obstruction by microsurgical 
techniques and by appropriate antibiotic treatment of 
the epididymitis. 
The most profound manifestation of a viability-
motility / disorder is necrospermia which fortunately 
is rare as there is no successful treatment. 
In patients with high ejaculate volumes (>3.5 
ml) and a secondary decrease in sperm count ( oli-
gospermia of less than 20 million/ ml), sperm density 
may be improved in about 80% of patients by use of 
the split-ejaculate technique. To collect a split or 
fractionated ejaculatory specimen, the patient is 
given two collection jars which are numbered #1 and 
#2 and s.ecured together with adhesive tape. The first 
one third of the ejaculate is collected in jar #1 and the 
remainder in jar #2. In 80% of patients, the sperm 
density will be significantly higher in the first portion 
of the ejaculate. The more favorable first portion may 
be delivered to the cervical os by a withdrawal coital 
technique (penis withdrawn from the vagina after the 
first spurt of ejaculate) or by insemination. In prop-
erly selected cases, pregnancy results are about 60%. 
Diffuse Abnormality of All Seminal Parameters 
The most common (60%) abnormal presentation 
of the semen analysis is a diffuse abnormality of all 
seminal parameters, that is, low sperm density, poor 
sperm viability, and more than 40% abnormal sperm 
forms. While nonspecific stress, subclinical endo-
crinopathy, and epididymal dysfunction or block are 
rare causes of diffuse seminal abnormality, they must 
nevertheless be considered and treated. 
However, the most common cause of diffuse 
seminal abnormality is a varicocele which accounts 
for one third of all cases of male infertility. The 
varicose enlargement of the veins of the spermatic 
cord (pampiniform plexus) is caused by valvular in-
competence of the internal spermatic vein with sec-
ondary retrograde flow of venous blood from the left 
renal vein into the internal spermatic vein. Because of 
the characteristic anatomy of the internal spermatic 
vein on the left side, varicoceles clinically occur more 
commonly on that side, that is, 80% left, 19% bilat-
eral, and I% right. Even if a varicocele is clinically 
limited to one side, venous dilatation occurs bilater-
ally due to the liberal cross-venous circulation of 
the pampiniform plexus, and the germinal epi-
thelium of both testes is pathologically affected. 
Varicoceles are best diagnosed with the patient 
standing erect as recumbency will decompress the 
varices. Small varicoceles can be more readily appre-
ciated by having the patient perform a Valsalva ma-
neuver. The diagnosis of small, subtle, and even sub-
clinical varicoceles can be facilitated by use of the 
Doppler stethoscope8 ; their diagnosis is equally im-
portant as there is no correlation between the size of 
the varicocele and the reduction in spermatogenesis 
based on testicular biopsies and semen analyses.9 
The mechanism whereby the varicocele causes 
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the deleterious effect on the germinal epithelium re-
mains unresolved. But of the two principal postulated 
causes (venous reflux of adrenal "toxins" vs increased 
intrascrotal temperatures secondary to venous 
stasis), the weight of recent.evidence favors elevated 
iritrascrotal temperatures as the probable cause of 
depressed spermatogenesis. 
The treatment of varicoceles is surgical and is 
directed at preventing retrograde venous flow by in-
terrupting the course of the internal spermatic vein at 
the level of the inguinal canal (I vanissevich method )10 
or the retroperitoneum (Palomo procedure ). 11 At-
tempts to directly remove the dilated scrotal veins 
through a transscrotal incision are to be avoided as 
they are not effective. 
The overall results of surgery are excellent with 
an improvement in semen quality of 70% and a preg-
nancy rate of 45%. 
Conclusion 
The prognosis for a previously infertile couple of 
achieving a pregnancy has improved substantially 
over the past 5-8 years. This has been made possible 
by a variety of diagnostic and therapeutic advances 
based on a greater understanding of t~sticular and 
epididymal function and disorder, hypothalamic-pi-
tuitary-gonadal interrelationships, and reproductive 
immunological and physiological factors. This 
knowledge, combined with a more comprehensive 
and systematic approach to the evaluation and man-
agement of the infertile male patient, has made pos-
sible the identification of the cause in 80% of patients 
as well as effective therapy in approximately 50% of 
coupfes under the age of 30 and approximately one 
third of those who are older. 
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Introduction 
Varying techniques of measurement coupled 
with lack of sufficient data have presented great diffi-
culties in the comparison of dental a rch dimensions 
obtained by different workers . Several a uthors 1- 7 
have attempted to delineate the arches. Lavelle et 
al7 measured the denta l arches of adults from several 
different ethnic groups and found little difference be-
tween the modern British Caucasian, Australian abo-
rigines, and North American Indians. They did, how-
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ever, see considerable differences between these 
modern populations a nd a group of Anglo-Saxons 
and a group of West Africans. 
Severa l studies8 - 10 have shown that there has 
been a reduction in the dimensions of the maxilla and 
mandible in modern times, a ltho ugh no reduction in 
tooth size was reported. A va riety of explanations 
have been put forth to explain this reduction in jaw 
size, among them evolutionary change" and con-
sistency of diet. 12 Others13 - 16 have shown that bone 
size is a ffected by mechanical stress or the lack of it. 
Since the modern di et is softer than that of past 
periods, it is reasoned tha t the soft diet requires less 
mechan ica l force to masticate a nd thus less mechani-
cal stress on the bone. This reduction in mechanical 
stress is assumed then to lead to reduction of jaw size. 
IOI 
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The present study was undertaken to investigate 
any changes in jaw size that occurred within the time 
period (2300 years) encompassed by the six pre-Co-
lumbian Peruvian cultures studied, and from that 
period to modern times. 
Materials and Methods 
Measurements were made on 84 adult maxillae 
and 114 adult mandibles from the pre-Columbian 
Peruvian material housed in the Museo Regional de 
lea, lea, Peru; these were made up of the following 
number of specimens from each of the six cultures: 
Paracas, 33 maxillae and 33 mandibles; Nazca, 6 
maxillae and 20 mandibles; Huari, 10 maxillae and 14 
mandibles; lea, 19 maxillae and 24 mandibles; Inca, 1 
maxilla and 2 mandibles; and Colonial, 15 maxillae 
and 21 mandibles. These six cultures flourished dur-
ing the following periods: Paracas, 600 BC-AD 100; 
Nazca, 100 BC-AD 800; Huari, AD 800.:_AD 1200; lea, 
AD 1200-AD 1450; Inca, AD 1450-AD 1532; and Colo-
nial, AD 1534-AD 1700. The dating of this material 
was carried out by both archaeological and C-14 
dating. Sex determinations were carried out as out-
lined by Allison and Gerszten, 17 although these could 
not be made accurately on some of the material; the 
values for this unsexed material appear in the tables 
under the heading "unknown." 
A total of 12jaw dimensions were measured; 4 of 
the maxilla and 8 of the mandible. The dimensions of 
arch width were measured between the centers of the 
corresponding teeth ori each side of the dental arch at 
the first premolars, first molars and second molars in 
both the maxillae and mandibles. Maxillary arch 
length was measured as outlined by Moyers.18 All 
measurements of the maxilla were made using dial 
calipers with an accuracy of 0.1 mm. Measurements 
of the mandible were taken19 using dial calipers with 
an accuracy of 0.1 mm and a mandibular board. 
While the measurements of the maxillary and man-
dibular arch widths at the first premolar and the first 
and second molars have been explained, the maxil-
lary arch length and the other mandibular measure-
ments must be defined. Maxillary arch length was 
measured by laying a bar across the central fossae of 
the first molars and measuring from the midline point 
along this bar to the incisal edge of the central in-
cisors. The mandibular angle is the angle between the 
standard horizontal plane and the ramal planes. The 
height of the ramus is from the most superior point 
on the left condyle to the standard horizontal plane 
(base of mandibular board) measured in the vertical 
plane. The body length is from the most anterior 
point in the symphysis area to the intersection of the 
standard horizontal and ramal planes. Bigonial width 
is the maximum width between the right and left 
gonion of the mandible. Bicondylar width is the max-
imum width between the lateral points of the right 
and left condyles. Although Hrdlicka4 states that bi-
condylar measurement is completely useless as the 
width is affected by the width of the skull at its base, 
many other authors have used bicondylar measure-
ment to define the mandibular arch and it is, there-
fore, included in this study. 
While 84 adult maxillae and 114 adult mandibles 
were measured, all totals for each of these measure-
ments will not come to these numbers because of 
missing teeth, fractured condyles, and other factors. 
Results 
Females in all cultures shown in Table I have the 
larger maxillary arch size in three of the four mea-
surements made. Maxillary arch width at the first 
premolar is larger in males in all cultures except the 
lea. No reduction of maxillary arch size is seen dur-
ing the approximately 2300-year period studied in 
this pre-Columbian Peruvian culture except in the 
width of the arch at the first molar; a reduction is seen 
here from the most ancient cultures studied to the 
most modern. The Inca culture exhibited the smallest 
maxillary arch length while the Huari culture, fol-
lowed closely by the N azca, sho.wed the greatest. The 
smallest arch width at the maxillary first premolar 
was seen in the Inca culture and the Colonial exhib-
ited the largest width. The largest arch width at the 
maxillary first molar was seen in the Nazca culture; 
the Colonial had the most narrow arch at the first 
molars. The H uari displayed the smallest and the lea 
the largest arch widths at the maxillary second mo-
lars. 
Table 2 gives five mandibular jaw measurements. 
The males of this pre-Columbian Peruvian popu-
lation exhibited the larger arch width at the first 
mandibular molar, the larger bigonial width, and the 
larger bicondylar width; other measurements pre-
sented (mandibular arch width at the first premolar 
and second molar) were similar in both sexes. A trend 
toward smaller mandibular jaw size was evident by a 
reduction in jaw size at the first molar, second molar, 
and bigonial widths . The N azca culture and the Para-
cas culture had the largest mandibular arch widths at 
the first premolars. The arch width at the first and 
second mandibular molars and the bigonial width 
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TABLE 1 
Maxillary Arch Measurements 
MAXILLARY MAXILLARY ARCH MAXILLARY ARCH MAXILLARY ARCH 
ARCH WIDTH AT WIDTH AT WIDTH AT 
LENGTH FIRST PREMOLAR FIRST MOLAR SECOND MOLAR 
CULTURE M F u T M F u T M F u T M F u T 
Paracas 
N 0 0 6 6 0 0 22 22 0 0 33 33 0 0 28 28 
Mean 25.4 25.4 39.6 39.6 48.8 48.8 53.6 53.6 
S.E. 0.9 0.9 0.6 0.6 0.6 0.6 2.8 2.8 
Nazca 
N 1 0 3 4 1 1 4 6 1 0 5 6 1 1 3 5 
Mean 22.7 27.2 26.1 36.1 36.1 39.9 39.8 53.4 49.6 50.3 57.0 51.4 54.3 54.3 
S.E. 0.0 1.1 1.4 0.0 0.0 0.7 1.0 0.0 0.3 0.7 0.0 0.0 1.8 1.3 
Huari 
N 1 0 4 5 4 6 1 2 7 10 1 2 6 9 
Mean 27.0 26.8 26.8 40.3 36.3 39.9 39.4 47.2 48.0 47.8 47.8 52.3 52.8 53.1 52.9 
S.E. 0.0 1.0 1.0 0.0 0.0 0.8 0.8 0.0 2.5 1.1 0.8 0.0 2.9 1.0 0.8 
lea 
N 1 9 4 14 1 13 1 15 I 11 7 19 1 7 2 10 
Mean 25.3 27.0 26.2 26.7 39.4 39.7 39 .0 39.6 50.7 48.7 45. 8 47.8 52.7 54.6 56.7 54.8 
S.E. 0.0 0.7 0.9 0.5 0.0 0.5 0.0 0.4 0.0 0.8 1.9 0.9 0.0 0.7 0.7 0.6 
Inca 
N 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 
Mean 24.8 24.8 36.9 36.9 47.9 47.9 54.2 54.2 
S.E. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Colonial 
N 0 12 3 15 2 12 0 14 1 10 2 13 1 11 0 12 
Mean 24.9 25.9 25.l 42.4 40.0 40.3 45.6 48.3 46.4 47 .8 52.3 53.6 53.5 
S.E. 0.4 1.2 0.4 0.3 0.6 0.5 0.0 0.6 1.0 0.5 0.0 0.7 0.7 
M =male 
F = female 
U = sex unknown 
T =total 
N = number 
S.E. = standard error 
were larger in the Nazca culture. The Huari, followed largest mandibular angle and the N azca the smallest 
closely by the N azca culture, had the greatest bi- m this pre-Columbian Peruvian population. The 
condylar width. The mandibular jaw size measure- Paracas culture shows the smallest ramus height and 
ments presented in Table 2 were consistently smaller the Colonial has the greatest. In examining the body 
in the Inca culture, although this figure can be mis- length measurements, the Nazca culture specimens 
leading due to the small sample size. have the longest mandibular body and the Inca have 
For three other mandibular jaw measurements the shortest. 
(mandibular angle, ramus height, and body length) 
presented in Table 3, the male specimens in this study Discussion 
have the larger measurements, although no reduction The size and shape of the dental arches are sub-
in jaw size is seen from the most ancient to the most ject to considerable variation.3 Factors such as 
modern cultures. The Paracas culture exhibits the growth20 and the location of the teeth in relation to 
0 
~ 
TABLE 2 
Mandibular Jaw Width 
MANDIBULAR ARCH MANDIBULAR ARCH MANDIBULAR ARCH 
WIDTH AT WIDTH AT WIDTH AT 
FIRST PREMOLAR FIRST MOLAR SECOND MOLAR BIGONIAL WIDTH BICONDYLAR WIDTH 
CULTURE M F u T M F u T M F u T M F u T M F u T 
Paracas 
N 0 0 19 19 0 0 18 18 0 0 14 14 I I 28 30 30 32 
Mean 34.9 34.9 44.8 44.8 49.8 49.8 96.0 96.0 93.3 93 .5 121.5 112.0 116.9 116.9 
S.E. 0.5 0.5 0.6 0.6 0.7 0.7 0.0 0.0 1.4 1.3 0.0 0.0 1.7 1.6 
Nazca 
N JO 12 I I 14 16 0 13 14 I I 18 20 I I 18 20 
Mean 35.5 35.4 34.8 34.9 48.2 43.7 46.5 46.4 55.7 51.4 51.7 90.0 s 1.5 95.0 95.8 111.0 118.0 118.5 118.J 
S.E. 0.0 0.0 0.5 0.4 0.0 0.0 0.4 0.4 0.0 0.4 0.6 0.0 0.0 2.1 2.4 0.0 0.0 1.3 1.3 
Huari C/J 
N I 2 8 I I 7 9 0 6 7 2 2 9 13 2 2 9 13 > 
Mean 32.5 33.8 34.1 33.9 42.6 42.3 45 .9 45.2 47.0 51.6 50.9 101.5 85.8 93.4 93.5 124.0 120.5 118.1 118.6 ~ 
S.E. 0.0 0.4 0.6 0.5 0.0 0.0 0.4 0.6 0.0 1.2 1.2 0.0 0.2 1.7 1.7 1.0 2.5 2.3 1.8 ....: tT'l 
;.:I 
lea tT'l 
N 2 14 4 20 I II 8 20 I JO 12 4 16 7 27 4 17 7 28 -l 
Mean 37.2 35.0 33.3 34.9 49.2 45.5 44.4 44.9 52.4 49.8 56.3 50.4 94.1 93 .6 90.4 92 .8 119.3 118.9 117.2 118.5 > 
S.E. 2.5 0.5 1.2 0.5 0.0 0.8 I. I 0.7 0.0 0 .6 0.0 0.8 3.0 1.3 2.2 1.4 1.8 1.2 3.0 I. I r:' 
'1' 
;.:I 
Inca tT'l I 
N 0 0 I 0 0 0 0 I I 0 I 2 0 2 ("') 
Mean 31.3 31.3 42 .6 42.6 48.J 48.1 94.0 88.0 91.0 118.5 111.0 114.8 0 r 
S.E. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 3.8 c 
s: 
Colonial l:C ;;: 
N 3 16 I 20 9 0 10 0 10 0 10 3 18 2 23 3 17 21 z 
Mean 34.3 35.0 32.8 34.7 43.8 43 .3 43.3 48.6 48 .6 95.2 90.0 80.8 88.0 121.7 116.7 115.0 117.3 
'1' 
S.E. 0.8 0.4 0.0 0.4 0.0 0.2 0.2 0.6 0.6 2.6 1.7 1.8 1.6 3.4 1.0 0 .0 1.0 tT'l 
;.:I 
c 
M =male < 
F = female ;;: 
U = sex unk nown z 
T = total 
._ 
> 
N = number ~ 
S.E. = standard error C/J 
N 
tT'l 
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TABLE 3 
Other Mandibular Measurements 
MANDIBULAR ANGLE RAM US HEIGHTH BODY LENGTH 
CULTURE M F u T M F u T M F u T 
Paracas 
N I I 31 33 I 30 32 I 29 31 
Mean 115.0 121.5 121.3 121.l 63.0 53.5 56.8 56.9 82.0 71.5 74.1 74.3 
S.E. 0.0 0.0 1.0 1.0 0 .0 0.0 1.2 l.l 0.0 0.0 1.0 1.0 
Nazca 
N 18 20 I 18 20 I 18 20 
Mean 118.0 114.5 118 .0 117 .9 60.0 55.0 60.1 59.8 68.5 68.0 78.3 77.3 
S.E. 0.0 0.0 1.7 1.5 0.0 0.0 1.0 1.0 0.0 0.0 1.3 1.3 
Huari 
N 2 2 IO 14 2 2 JO 14 2 2 JO 14 
Mean 123.5 116.5 119.8 119.8 60.8 55.8 59.6 59.2 76.2 76.3 73. l 74.7 
S.E. 3.0 5.0 1.7 1.4 2.3 1.8 2.3 1.7 1.2 2.8 2.5 2.1 
lea 
N 4 16 5 25 4 17 6 27 4 16 8 28 
Mean 119.5 116.9 122.0 118.3 59.0 60.2 59.4 60.6 78.9 75.3 73.3 74.J 
S.E. 3.8 1.3 3.5 2.4 I. 7 0.8 1.8 0.6 2.1 1.0 2.4 1.2 
Inca 
N 0 I I 2 0 I 2 0 I 2 
Mean 121.5 116.0 118.8 54.5 59.5 57.0 71.0 74.0 72.5 
S.E. 0.0 0.0 2.8 0 .0 0.0 2.5 0.0 0.0 1.5 
Colonial 
N 3 17 2 22 3 16 2 21 3 16 2 19 
Mean 117.0 117.5 124.5 118.5 62.3 60.0 56.3 60.0 74.8 75.6 76.0 75.0 
S.E. 5.6 1.6 0.0 1.5 2.0 I. I 1.3 1.0 1.4 1.0 0.0 0.0 
M = male 
f" = female 
U = sex unknown 
T = total 
N = number 
S.E. = standard error 
the basal bone21 have been shown to influence arch mensions in recent times in Europe. Several of these 
size and shape. Gould and Picton22 pointed out that studies have also shown that this reduction was not 
the equilibrium between the adjacent orofacial mus- accumpanied by a corresponding diminution in tooth 
culature and the arch affects its size and shape. The size. The present study shows a reduction in the width 
degree of tooth attrition or abrasion has also been of the maxillary arch at the first molar during the 
noted to affect arch size and shape. Several of these time period studied. The most recent pre-Columbian 
factors, particularly attrition and growth, could have Peruvian cultures also showed a reduction in jaw size 
influenced jaw size and shape in this study, giving the in the mandible as noted in the diminution of arch 
wide degree of variation seen between and within the width at the first and second molars and in the bigo-
cultural groups. nial width. This reduction in jaw dimensions in more 
Studies of Swedish maxillae and mandibles,8 recent times was, however, accompanied by a corre-
British palates10 and dental arches,23 and European sponding reduction in tooth size.25 
mandibles,24 have all shown a reduction in jaw di- Many authors26•27 •12 have blamed this reduction 
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of jaw size on soft diet. The soft diet requires little 
mechanical force to masticate and thus less stimula-
tion of the bone. If changes in the consistency of the 
diet were the principal factor responsible for this 
reduction , then the mandibular ramus would be re-
duced in size.28 One should bear in mind that the 
mandibular ramus is the point of insertion of the 
muscles of mastication. In the present study, while a 
reduction in jaw size was exhibited by the more mod-
ern cultures as compared to the earlier ones, a reduc-
tion in the mandibular ramus was not seen. Although 
the presumptive evidence is strong that the reduction 
of the jaws is the direct result of less mecha nical stress 
produced by the mastication of a soft diet in some 
studies, the possi bility that genetic change may also 
be involved cannot be completely ruled out. Archae-
ological study of these cultures has shown that while 
differences in diet were seen between " inland" and 
"coastal" cultures, little change occurred in the diet 
within these groups over the period studied. The in-
flux of outside groups of individuals into the cultures 
studied, either by conquest or peaceful assimilation, 
could have resulted in the acquisition of new genetic 
traits, which leaves open the possibility that genetic 
change has influenced the reduction in jaw size. 
Conclusion 
In this study of 84 adult maxillae and 114 adult 
mandibles a reduction in jaw dimensions was seen in 
the more modern cultures. This reduction could not 
be explained by diet alone and the possibility that 
genetic change from gene mutation or population 
migration is suggested . Due to the small number of 
male specimens identified in this population, few, if 
a ny, valid comparisons can be made between the 
sexes concerning jaw dimensions. Future studies 
should be conducted to remedy this discrepancy. 
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When spasm and pain associated with irritable bowel 
syndrome call for treatment beyond your counseling and 
reassurance, Donnatal may prove to be a helpful adjunct. 
The smooth central sedation and prompt peripheral 
antispasmodic/anticholinergic action of Donnatal may 
provide this symptomatic relief necessary to help calm 
the waves ... and quell the spasm. 
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